var title_f7_25_7568="Red wale Endosc";
var content_f7_25_7568=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endoscopic \"red wale\" sign on esophageal varices",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 274px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopy of a chain of varices in the distal esophagus showing erythematous raised areas indicating an increased risk of bleeding.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eric D Libby, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_25_7568=[""].join("\n");
var outline_f7_25_7568=null;
var title_f7_25_7569="Glutethimide: International drug information";
var content_f7_25_7569=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Glutethimide: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4089070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alfimid (HR);",
"     </li>",
"     <li>",
"      Glimid (PL);",
"     </li>",
"     <li>",
"      Noxyron (CZ, HU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F4089071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Hypnotic, Nonbenzodiazepine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F4089072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term treatment of insomnia",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F4089074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Adults: 250-500 mg at bedtime, dose may be repeated but not less than 4 hours before intended awakening; maximum: 1 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Elderly/debilitated patients: Total daily dose should not exceed 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F4089075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 250 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10454 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-9D3D6B0F7E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_25_7569=[""].join("\n");
var outline_f7_25_7569=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4089070\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4089071\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4089072\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4089074\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821173\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4089075\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10454\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10454|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_25_7570="Lichen planus Koebner";
var content_f7_25_7570=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F68060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F68060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Koebner reaction in lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patients with lichen planus can exhibit the Koebner reaction, in which lesions develop in areas of trauma. In this patient, the Koebner reaction resulted from scratching.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_25_7570=[""].join("\n");
var outline_f7_25_7570=null;
var title_f7_25_7571="Mitral stenosis as heard at the apex";
var content_f7_25_7571=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1164px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/55136/ms_apex_conv.mp4?title=Mitral+stenosis+as+heard+at+the+apex\" style=\"width:516px;height:464px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 528px\">",
"   <div class=\"ttl\">",
"    Mitral stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 508px; height: 279px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electrocardiogram and phonocardiogram of mitral stenosis as heard at the apex. A pre-systolic murmur or rumble of mitral stenosis precedes S1, a result of increased blood flow from atrial contraction. Following S2 (closure of the aortic and pulmonic valves) is the opening of the stenotic mitral valve (snap) and the low pitch mid diastolic murmur or rumble of mitral stenosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Provided by John M Criley, MD, The Physiological Origins of Heart Sounds and Murmurs, Little, Brown, Boston, 1996, 1-800-527-0145. This program contains a complete interactive tutorial integrating over 200 heart sounds and murmurs with cineangiographic, echo-Doppler, and hemodynamic motion picture sequences.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_25_7571=[""].join("\n");
var outline_f7_25_7571=null;
var title_f7_25_7572="Granular parakeratosis";
var content_f7_25_7572=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F73591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F73591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Granular parakeratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hyperkeratotic red-brown papules are present in the axilla.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_25_7572=[""].join("\n");
var outline_f7_25_7572=null;
var title_f7_25_7573="Gram stain sputum 8A answer";
var content_f7_25_7573=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66300%7EID%2F77055%7EID%2F56963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66300%7EID%2F77055%7EID%2F56963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pseudomonas aeruginosa in sputum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 353px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of sputum (x1000) shows inflammatory cells, Gram negative bacilli, and large gram-positive yeast and pseudohyphae. Both Pseudomonas aeruginosa and Candida albicans grew from this specimen. P. aeruginosa characteristically produces a green pigment on Mueller-Hinton agar; some strains have a mucoid colony phenotype.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pigment produced by pseudomonas aeruginosa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 328px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The green pigment produced by Pseudomonas aeruginosa is easily seen on Mueller-Hinton agar plate used for disk antimicrobial susceptibility testing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pseudomonas aeruginosa on MacConkey agar",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 334px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Compare the mucoid (above) and non-mucoid (below) strains of Pseudomonas aeruginosa. Patients with cystic fibrosis often have mucoid P. aeruginosa in their sputum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_25_7573=[""].join("\n");
var outline_f7_25_7573=null;
var title_f7_25_7574="Monoamine oxidase inhibitors (MAOIs) for treating depressed adults";
var content_f7_25_7574=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Monoamine oxidase inhibitors (MAOIs) for treating depressed adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/25/7574/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/25/7574/contributors\">",
"     Michael Hirsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/25/7574/contributors\">",
"     Robert J Birnbaum, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/25/7574/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/25/7574/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/25/7574/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/25/7574/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/25/7574/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of antidepressant medications has proceeded through several historical phases. The older antidepressants such as monoamine oxidase inhibitors and early tricyclic antidepressants were discovered largely by serendipity. While effective antidepressants, these medications affect a wide range of neurotransmitter systems and cause many undesirable side effects. Subsequently, psychopharmacologic research and development efforts focused upon identifying the neurochemical properties associated with the antidepressant actions of these medications and upon developing compounds with variations on their chemical structure.",
"   </p>",
"   <p>",
"    As theories were developed about the neurotransmitter systems involved in depression (eg, the monoamines serotonin, norepinephrine, and dopamine), drug development techniques progressed in parallel, leading to the formation of compounds with targeted affinities for receptors involved in specific aspects of monoaminergic neurotransmission (eg, the selective serotonin reuptake inhibitors). The incidence of side effects were greatly reduced since these medications had less effect upon other types of receptors (eg, cholinergic, histaminic, alpha adrenergic).",
"   </p>",
"   <p>",
"    Advances in the basic neurosciences have further elucidated the pathophysiology of depression and have expanded our view of the many neurotransmitter systems involved in affective illness. Current evidence suggests that the initial receptor and neurotransmitter effects of antidepressants lead to \"downstream\" changes in protein production at a cellular level; these changes in turn appear to influence elements of neuronal protection and synaptic plasticity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7574/abstract/1\">",
"     1",
"    </a>",
"    ]. Modern psychopharmacologic research has capitalized on this information, leading to the development of \"designer\" antidepressants with effects on specific combinations of selected neurotransmitter and neuropeptide systems [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7574/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pharmacology of MAO inhibitors is reviewed here. The pharmacology and use of selective serotonin reuptake inhibitors (SSRIs), heterocyclic, serotonin-norepinephrine reuptake inhibitors (SNRIs), other antidepressants, and the serotonin syndrome, are discussed separately. Switching and discontinuing antidepressants, and an overview of options for treatment in depression are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=see_link\">",
"     \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=see_link\">",
"     \"Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=see_link\">",
"     \"Serotonin syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26135?source=see_link\">",
"     \"Antidepressant medication in adults: Switching and discontinuing medication\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MONOAMINE OXIDASE INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monoamine oxidase inhibitors (MAOIs) were the first class of antidepressants in clinical use. They were discovered in 1952 after iproniazid (a derivative of the antibiotic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    ) was found to be ineffective for treating tuberculosis, but was a potent antidepressive agent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7574/abstract/1\">",
"     1",
"    </a>",
"    ]. The next MAOI,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/29/32215?source=see_link\">",
"     tranylcypromine",
"    </a>",
"    , was identified as an antidepressant after it proved to be ineffective as a nasal decongestant. What these two medications have in common is the property of irreversibly blocking monoamine oxidase, the enzyme responsible for the oxidative deamination of neurotransmitters such as serotonin, norepinephrine, and dopamine. This property is thought to be largely responsible for the MAOIs' antidepressant effects.",
"   </p>",
"   <p>",
"    The enzyme MAO comes in two forms, MAOa and MAOb. MAOb metabolizes phenylethylamine and, together with MAOa, breaks down dopamine. MAOa is responsible for the breakdown of serotonin and norepinephrine.",
"   </p>",
"   <p>",
"    MAO is distributed in tissues throughout the body. The blockade of MAOIa in the gastrointestinal tract is responsible for the \"cheese reaction\" associated with MAOIs. This refers to a severe hypertensive crisis that can occur after patients on MAOIs ingest foods containing the sympathomimetic tyramine. Tyramine is usually metabolized in the gastrointestinal tract, but the blockade of MAOa allows it to flow into the general circulation. Although the accepted \"MAOI diet\" has been liberalized in recent years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7574/abstract/2\">",
"     2",
"    </a>",
"    ], there are still several dietary restrictions to which patients on these medications must adhere.",
"   </p>",
"   <p>",
"    MAOIs are not considered to be first-line antidepressant medications because of the dietary restrictions (",
"    <a class=\"graphic graphic_table graphicRef80345 \" href=\"UTD.htm?26/39/27259\">",
"     table 1",
"    </a>",
"    ), drug-drug interactions, and their relatively extensive side-effect profile. MAOIs have potent hypotensive effects, and up to 50 percent of patients experience dizziness. This is particularly important when treating elderly patients as they may be both more sensitive to the hypotensive effects and more likely to fall and sustain fractures. Other common side effects are dry mouth, gastrointestinal upset, urinary hesitancy, headache, and myoclonic jerks. MAOIs suppress REM sleep, but the clinical significance of this is unknown. Afternoon fatigue is common.",
"   </p>",
"   <p>",
"    Despite their side-effect profile, MAOIs can be particularly useful agents for the treatment of \"atypical\" depression (eg, depression with hyperphagia, hypersomnia, leaden paralysis, and rejection sensitivity), and are frequently effective in treatment-resistant depressed patients.",
"   </p>",
"   <p>",
"    Several compounds with selective MAOa and MAOb inhibiting properties have been developed, as well as reversible MAOIs. Properties of the MAOIs most commonly prescribed in the United States for treatment of depression are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Tranylcypromine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/29/32215?source=see_link\">",
"     Tranylcypromine",
"    </a>",
"    has a chemical structure similar to amphetamine and has some stimulant properties. It is predominantly an irreversible inhibitor of MAOa, but also irreversibly inhibits MAOb to a degree. It also appears to block reuptake of serotonin and catecholamines.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/29/32215?source=see_link\">",
"     Tranylcypromine",
"    </a>",
"    has a rapid onset of MAOI activity, although clinical effects may not be present for two to four weeks. The mechanism by which tranylcypromine is metabolized is not clearly understood. The medication appears to maximally inhibit MAO activity at even subtherapeutic doses.",
"   </p>",
"   <p>",
"    A conservative starting dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/29/32215?source=see_link\">",
"     tranylcypromine",
"    </a>",
"    is 10 mg daily. If tolerated, the dose can then be raised to 30 mg daily in divided doses. The dose can be further increased by 10 mg every week up to 60 mg daily as needed. Although some MAO activity is restored three to five days after discontinuing the medication, it is prudent to allow two weeks for full restoration of MAO activity after stopping tranylcypromine.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/29/32215?source=see_link\">",
"     Tranylcypromine",
"    </a>",
"    shares the side-effect profile of other MAOIs. It has the potential to interact with sympathomimetics leading to hypertensive crisis, to interact with serotonergic medications leading to the serotonin syndrome (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=see_link\">",
"     \"Serotonin syndrome\"",
"    </a>",
"    ), and can cause dose-related hypotension, sexual dysfunction, and sleep disturbance. Patients on tranylcypromine may have transient blood pressure increases after dosing, which subsides in three to four hours.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/29/32215?source=see_link\">",
"     Tranylcypromine",
"    </a>",
"    is more likely than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/42/20135?source=see_link\">",
"     phenelzine",
"    </a>",
"    to cause activation and insomnia, so the last dose should be given early in the day. It is less likely than phenelzine to cause weight gain; some patients even experience weight loss.",
"   </p>",
"   <p>",
"    Care must be taken in starting and stopping",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/29/32215?source=see_link\">",
"     tranylcypromine",
"    </a>",
"    , to avoid precipitating a hypertensive reaction of serotonin syndrome (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Initiating or discontinuing MAO Inhibitors'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Phenelzine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/42/20135?source=see_link\">",
"     Phenelzine",
"    </a>",
"    is a substituted hydrazine that irreversibly inhibits MAOa and MAOb. The metabolism of phenelzine is not clearly understood.",
"   </p>",
"   <p>",
"    Patients can be started on 15 mg on day one, and increased to 15 mg three times daily over two to three days as tolerated. The dose can be titrated upwards to a dose of 60 to 90 mg as tolerated.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/42/20135?source=see_link\">",
"     Phenelzine",
"    </a>",
"    shares the common MAOI side effects of potential for interactions with sympathomimetics leading to hypertensive crisis, interactions with serotonergic medications leading to serotonin syndrome (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=see_link\">",
"     \"Serotonin syndrome\"",
"    </a>",
"    ), dose-related hypotension, sexual dysfunction, and sleep disturbance. It may cause less insomnia than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/29/32215?source=see_link\">",
"     tranylcypromine",
"    </a>",
"    , but it seems more likely to cause weight gain, sedation, and sexual dysfunction. Phenelzine can very rarely cause hepatotoxicity.",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/42/20135?source=see_link\">",
"     phenelzine",
"    </a>",
"    is correlated with at least 80 to 85 percent inhibition of platelet MAOb activity, which typically requires a dose of at least 60 mg per day [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7574/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. However, there is a wide range of percent inhibition of the MAO enzyme for a particular dose among different patients. Thus, monitoring MAOb platelet inhibition (when available) can help guide treatment if full therapeutic doses for adequate duration (eg, four to eight weeks) fail to produce a clinical response,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    side effects limit dose increases. Clinical antidepressant effects may not be seen until three to six weeks of continued treatment.",
"   </p>",
"   <p>",
"    Care must be taken in starting and stopping",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/42/20135?source=see_link\">",
"     phenelzine",
"    </a>",
"    , to avoid precipitating a hypertensive reaction or the serotonin syndrome (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Initiating or discontinuing MAO Inhibitors'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Selegiline",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25448?source=see_link\">",
"     Selegiline",
"    </a>",
"    is a selective MAOb inhibitor at low doses and a non-selective MAO inhibitor at higher doses. Selegiline primarily increases dopaminergic neurotransmission at lower doses, and increases serotonergic, noradrenergic, and dopaminergic neurotransmission at higher doses. Low dose selegiline does not appear to have antidepressant properties and is primarily used in treatment of Parkinson disease; it does not require dietary restrictions because of its lack of inhibition of MAOa.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25448?source=see_link\">",
"     Selegiline",
"    </a>",
"    functions as a traditional MAOI at higher dose. It inhibits both MAOa and MAOb, has antidepressant properties, and, when taken orally, requires dietary restrictions to prevent hypertensive reactions.",
"   </p>",
"   <p>",
"    A transdermal patch form of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25448?source=see_link\">",
"     selegiline",
"    </a>",
"    (EMSAM) was approved by the FDA in 2006 for use in the treatment of depression [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7574/abstract/6\">",
"     6",
"    </a>",
"    ]. Daily transdermal administration of selegiline allows for dosing that is high enough to produce antidepressant effects (by inhibiting MAOa and MAOb), but bypasses the gut. Direct inhibition of MAOa in the GI tract is avoided when transdermal selegiline is used at a dose of 6",
"    <span class=\"nowrap\">",
"     mg/24",
"    </span>",
"    hours.",
"   </p>",
"   <p>",
"    There are no dietary restrictions when transdermal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25448?source=see_link\">",
"     selegiline",
"    </a>",
"    is used at the recommended starting and target dose, 6",
"    <span class=\"nowrap\">",
"     mg/24",
"    </span>",
"    hours. MAOI dietary restrictions are required if the 9",
"    <span class=\"nowrap\">",
"     mg/24",
"    </span>",
"    hours or 12",
"    <span class=\"nowrap\">",
"     mg/24",
"    </span>",
"    hours patch is used, because of limited clinical and experimental experience with higher doses. While it is not known if doses higher than 6",
"    <span class=\"nowrap\">",
"     mg/24",
"    </span>",
"    hours are clinically more effective, clinicians may prescribe higher doses based on clinical judgment. Dose increases should occur in increments of 3",
"    <span class=\"nowrap\">",
"     mg/24",
"    </span>",
"    hours (up to a maximum dose of 12",
"    <span class=\"nowrap\">",
"     mg/24",
"    </span>",
"    hours) at intervals of no less than two weeks.",
"   </p>",
"   <p>",
"    Care must be taken in starting and stopping",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25448?source=see_link\">",
"     selegiline",
"    </a>",
"    , to avoid precipitating a hypertensive reaction of serotonin syndrome (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Initiating or discontinuing MAO Inhibitors'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25448?source=see_link\">",
"     selegiline",
"    </a>",
"    patch is the first transdermal antidepressant and is of particular benefit to patients who cannot take oral medications. Patients who respond to the 6",
"    <span class=\"nowrap\">",
"     mg/24",
"    </span>",
"    hour dose may avoid dietary restrictions. Limited data are available to determine which patients are likely to respond at this dose, and whether higher doses, necessitating MAOI dietary restrictions, are indicated for patients who do not respond.",
"   </p>",
"   <p>",
"    Two randomized studies, both using the 6",
"    <span class=\"nowrap\">",
"     mg/24",
"    </span>",
"    hour patch, found that short term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25448?source=see_link\">",
"     selegiline",
"    </a>",
"    (six and eight weeks), compared to placebo, improved depression scores and, in patients with less severe depression, increased remission rates [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7574/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Initiating or discontinuing MAO Inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antidepressants should be stopped two weeks before beginning",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/29/32215?source=see_link\">",
"     tranylcypromine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/42/20135?source=see_link\">",
"     phenelzine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25448?source=see_link\">",
"     selegiline",
"    </a>",
"    to avoid precipitating a hypertensive reaction or the serotonin syndrome (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=see_link\">",
"     \"Serotonin syndrome\"",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7574/abstract/9\">",
"     9",
"    </a>",
"    ]. Because of its longer half life,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    should be stopped five weeks before using a MAO inhibitor. In addition, two weeks should elapse after discontinuing tranylcypromine, phenelzine, or selegiline before starting another antidepressant or stopping the MAOI diet. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26135?source=see_link\">",
"     \"Antidepressant medication in adults: Switching and discontinuing medication\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=see_link\">",
"       \"Patient information: Depression in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;MAOIs are not considered to be first-line antidepressant medications because of the dietary restrictions, drug-drug interactions, and their relatively extensive side-effect profile. They may have a role in treatment of atypical depression and treatment-resistant depression.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Himmelhoch, J. Monoamine oxidase inhibitors. In: Comprehensive Textbook of Psychiatry / VI, KA Sadock, Editor. Williams &amp; Wilkins: Baltimore 1995; 2038.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7574/abstract/2\">",
"      Gardner DM, Shulman KI, Walker SE, Tailor SA. The making of a user friendly MAOI diet. J Clin Psychiatry 1996; 57:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7574/abstract/3\">",
"      Horst WD, Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord 1998; 51:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7574/abstract/4\">",
"      Bresnahan DB, Pandey GN, Janicak PG, et al. MAO inhibition and clinical response in depressed patients treated with phenelzine. J Clin Psychiatry 1990; 51:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7574/abstract/5\">",
"      Ravaris CL, Nies A, Robinson DS, et al. A multiple-dose, controlled study of phenelzine in depression-anxiety states. Arch Gen Psychiatry 1976; 33:347.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/bbs/topics/NEWS/2006/NEW01326.html.Selegilin (Accessed May 6, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7574/abstract/7\">",
"      Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry 2002; 159:1869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7574/abstract/8\">",
"      Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry 2003; 64:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7574/abstract/9\">",
"      Transdermal selegiline (Emsam). Med Lett Drugs Ther 2006; 48:41.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1715 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-11D65C23BF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_25_7574=[""].join("\n");
var outline_f7_25_7574=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MONOAMINE OXIDASE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Tranylcypromine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Phenelzine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Selegiline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Initiating or discontinuing MAO Inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/1715\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/1715|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/39/27259\" title=\"table 1\">",
"      MAOI drugs and foods",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26135?source=related_link\">",
"      Antidepressant medication in adults: Switching and discontinuing medication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=related_link\">",
"      Patient information: Depression in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=related_link\">",
"      Serotonin syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=related_link\">",
"      Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=related_link\">",
"      Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=related_link\">",
"      Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_25_7575="Anatomy of the cricothyroid membrane";
var content_f7_25_7575=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F82088&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F82088&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Anatomy of the cricothyroid membrane",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 505px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The cricothyroid muscle is bilateral and depicted on one side for illustrative purposes.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_25_7575=[""].join("\n");
var outline_f7_25_7575=null;
var title_f7_25_7576="Cryofibrinogenemia";
var content_f7_25_7576=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cryofibrinogenemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/25/7576/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/25/7576/contributors\">",
"     Stanford L Peng, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/25/7576/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/25/7576/contributors\">",
"     Mark H Wener, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/25/7576/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/25/7576/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/25/7576/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;When plasma is refrigerated at 4&ordm;C for up to 72 hours, proteins may precipitate (cryoprecipitate). If refrigerated serum and plasma both form a precipitate, then the precipitated proteins are referred to as cryoglobulins (CGs). If, however, precipitation develops after refrigeration of plasma but does not occur in cold serum, the plasma precipitate is referred to as cryofibrinogen (CF).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Cryoprecipitates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both CGs and CF typically redissolve with warming to 37&ordm;C, but the components of cryofibrinogen and cryoglobulin differ. CGs typically contain immunoglobulins and complement components. Although CF may also contain immunoglobulins, CF is characteristically composed of fibrinogen, fibrin, fibronectin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fibrin degradation products [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7576/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. By definition, CF is undetectable in serum.",
"   </p>",
"   <p>",
"    Some cryoprecipitates, particularly CGs may not completely redissolve when warmed. The residual material may be composed of fibrin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Cryoglobulinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;As defined above, a person whose serum and plasma form cryoprecipitates is referred to as having cryoglobulinemia. Three different types of CGs are recognized and the pathogenesis, clinical manifestations, and treatment associated with each type are discussed elsewhere. The following is a brief summary of the types of cryoglobulinemia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I cryoglobulinemia, in which there is a monoclonal immunoglobulin that is most often due to underlying multiple myeloma or Waldenstr&ouml;m&rsquo;s macroglobulinemia. In multiple myeloma, cryoglobulin-induced glomerular disease must be distinguished from primary amyloidosis and from light chain deposition disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27400?source=see_link\">",
"       \"Types of renal disease in multiple myeloma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Type II cryoglobulinemia or essential mixed cryoglobulinemia, in which the cryoglobulin contains both a polyclonal IgG (which may either act as an antigen or be directed against an antigen) and a monoclonal IgM rheumatoid factor directed against the IgG. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34040?source=see_link\">",
"       \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36682?source=see_link\">",
"       \"Treatment of the mixed cryoglobulinemia syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Type III cryoglobulinemia, in which there is also a mixed cryoglobulin, but both the IgG and the rheumatoid factor IgM are polyclonal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Cryofibrinogenemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A person whose plasma, but not serum, forms a cryoprecipitate is referred to as having cryofibrinogenemia. Some people with cryofibrinogenemia are asymptomatic, while others have clinical features resulting from thrombosis. Cryofibrinogenemia may also be associated with other disease processes, such as malignancy, infection, connective tissue and autoimmune disorders.",
"   </p>",
"   <p>",
"    The remainder of this topic review addresses issues related to the measurement of CF and the significance of cryofibrinogenemia in healthy people and patients in whom such cryoprecipitates play a clinically important pathologic role.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MEASUREMENT OF CRYOFIBRINOGEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The accuracy of CF assays is critically dependent upon the method of collection. Collected blood should be anticoagulated with EDTA, citrate or oxalate, and maintained at 37&ordm;C until the plasma is collected. Ideally this includes separation in a temperature controlled centrifuge. The plasma is placed in a Wintrobe tube and refrigerated at 4&ordm;C for 72 hours, at which time the \"cryocrit\" is quantitated by centrifuging the specimen while it remains cooled to 4&ordm;C.",
"   </p>",
"   <p>",
"    A positive result is typically reported as percentage of cryocrit (as measured in a graduated Wintrobe tube). Quantitation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    identification of the individual CF components may be facilitated by use of a number of techniques, such as chromatography, immunodiffusion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    electrophoresis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7576/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The formation of a cryoprecipitate before the plasma is assayed can lead to a falsely negative result if collection is not performed at 37&ordm;C. A false positive result may occur if",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is present as an anticoagulant in the blood collection tube or from therapeutic use, because it can complex with fibrinogen, fibrin, and fibronectin [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7576/abstract/6-10\">",
"     6-10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several disease processes have been associated with cryofibrinogenemia, which may be classified as primary (or essential or idiopathic) versus secondary (",
"    <a class=\"graphic graphic_table graphicRef72157 \" href=\"UTD.htm?21/56/22413\">",
"     table 1",
"    </a>",
"    ). The most frequently associated disorders include malignancy, infections, and inflammatory processes such as connective tissue diseases or thromboembolic conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7576/abstract/11\">",
"     11",
"    </a>",
"    ]. These disorders may or may not be evident at the time of diagnosis of CF, but become clinically apparent later [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7576/abstract/12\">",
"     12",
"    </a>",
"    ]. Rare familial forms have been described, but their molecular bases remain unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7576/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The underlying pathogenesis of sporadic CF is uncertain. Pathology in cryofibrinogenemia is attributed to \"in situ\" thrombosis mediated by circulating CF. The major components of CF include fibrinogen, fibrin, and fibronectin (also called cold-insoluble globulin, or CIg) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7576/abstract/3\">",
"     3",
"    </a>",
"    ]. Fibronectin has been characterized functionally by the ability to bind to fibrin and fibrinogen, and \"in vitro\" studies have suggested that fibronectin acts as a nucleus for the cold-induced cryoprecipitation of fibrinogen-fibrin complexes. Other components of CF include alpha(1)-antitrypsin, and alpha(2)-macroglobulin, both of which can inhibit plasmin activity and thereby contribute to thrombus formation.",
"   </p>",
"   <p>",
"    Fibronectin within the CF complex may also interact with circulating immunoglobulins or immune complexes, and thus contribute an inflammatory component to the potentially prothrombotic nature of CF [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7576/abstract/6,16\">",
"     6,16",
"    </a>",
"    ]. An immunologic mechanism may play a significant role in the pathophysiology of cryofibrinogenemia associated with malignancies, infections, and connective tissue diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL SIGNIFICANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, CF has been associated with a number of disease states, but may also be present in otherwise healthy individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Asymptomatic cryofibrinogenemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some \"cases\" of cryofibrinogenemia are discovered incidentally upon testing of asymptomatic individuals. Several studies have estimated that the prevalence of asymptomatic CF is approximately 2 to 9 percent of normal subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7576/abstract/5,17-19\">",
"     5,17-19",
"    </a>",
"    ]. In such studies, amounts of CF were typically less than 50",
"    <span class=\"nowrap\">",
"     mg/L,",
"    </span>",
"    contrasting significantly with CF in patients with symptoms referable to cryofibrinogenemia, in whom levels often exceed 1",
"    <span class=\"nowrap\">",
"     g/L.",
"    </span>",
"    Indeed, significant levels of CF are quite rare in clinical practice, even among patients with cryoprecipitates: one study analyzed 335 patient samples with measurable cryoprecipitates, identifying only one as CF, the remainder as CGs [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7576/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signs and symptoms of circulating CF reflect cutaneous manifestations of cold-induced thromboses, increases in blood viscosity,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vascular reactivity (",
"    <a class=\"graphic graphic_table graphicRef81681 \" href=\"UTD.htm?23/36/24139\">",
"     table 2",
"    </a>",
"    ). Findings may include painful ulcers, purpura, livedo reticularis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    painful or pruritic erythema (perniosis) of the extremities, as well as arthralgias [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7576/abstract/17-25\">",
"     17-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several other conditions have been associated with cryofibrinogenemia, though a causal relationship has not been proven. Among these, thrombotic events including stroke, myocardial infarction, limb and bowel ischemia or infarction, thrombophlebitis, pulmonary emboli, and ocular thrombi including retinal arterial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    venous occlusions are described most frequently [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7576/abstract/19,26,27\">",
"     19,26,27",
"    </a>",
"    ]. Pseudotumor cerebri and cold urticaria have also been associated with the presence of CF [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7576/abstract/28-30\">",
"     28-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cryoprecipitates that contain both CF and immunoglobulins are more often found in association with secondary cryofibrinogenemia. This was illustrated by a study of 49 patients with cryofibrinogenemia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7576/abstract/5\">",
"     5",
"    </a>",
"    ]. Secondary cryofibrinogenemia, associated with connective tissue diseases, infections, or malignancies, was more common among patients with immunoglobulin containing CF when compared to patients with isolated CF (79 versus 47 percent, respectively). The absence of immune components in the cryoprecipitate was associated with an increased incidence of cutaneous (77 versus 58 percent) and thrombotic (13 versus 3 percent) symptoms, typically characterized by cold-induced, painful, recurrent skin ulcers.",
"   </p>",
"   <p>",
"    Among hepatitis C virus (HCV) infected patients, the presence of CF is common, and is closely correlated with CGs. In a study of 143 French patients with HCV infection, 53 (37 percent) had CF levels &gt; 50",
"    <span class=\"nowrap\">",
"     mg/L;",
"    </span>",
"    47 of these CF-positive patients (89 percent), had positive tests for CGs [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7576/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsies of skin lesions reveal occlusion of the small dermal vessels by fibrin and platelet thrombi with a perivascular mononuclear infiltrate [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7576/abstract/32\">",
"     32",
"    </a>",
"    ]. Similar findings have been described in the lung, muscle and kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7576/abstract/25,33\">",
"     25,33",
"    </a>",
"    ]. True leukocytoclastic vasculitis is atypical, though occasionally described [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7576/abstract/32,34\">",
"     32,34",
"    </a>",
"    ]. Other histopathologic features have been noted in cases with distal cold-induced painful",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pruritic lesions (perniosis) including interface dermatitis, lymphocytic infiltrates, dilated vessels, and mucinosis; these features are nonspecific and were shared by patients with perniosis due to systemic lupus erythematosus, antiphospholipid syndrome, and hypergammaglobulinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7576/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence or absence of CF is determined by laboratory testing. However, making a diagnosis of clinically significant cryofibrinogenemia requires that in addition to a having a circulating CF, a patient also have suggestive clinical features and histopathological demonstration of typical \"in situ\" thrombi.",
"   </p>",
"   <p>",
"    Diagnostic criteria proposed for essential CF include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7576/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Compatible clinical presentation",
"     </li>",
"     <li>",
"      Presence of cryofibrinogen in plasma",
"     </li>",
"     <li>",
"      Absence of cryoglobulins",
"     </li>",
"     <li>",
"      Absence of causes of secondary CF (eg, infection, neoplasm)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Angiographically demonstrated abrupt complete occlusion of small to medium-sized arteries, or typical pathologic findings on biopsy of affected tissue, are also supportive findings [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7576/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Pathology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of cryofibrinogenemia encompasses a spectrum of cold-induced injury, thrombotic and embolic disorders",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vasculopathies, including:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Frostbite",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tissue injury from cold exposure can affect skin and deeper structures, typically on the face and extremities. Blistering, necrosis, and gangrene may result [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7576/abstract/35\">",
"     35",
"    </a>",
"    ]. A history of cold exposure may be absent in cases related to drug or alcohol use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37671?source=see_link\">",
"     \"Frostbite\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Atherosclerotic peripheral vascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of atherosclerosis is often associated with symptoms of vascular claudication, and physical findings of diminished peripheral pulses. Limb-threatening ischemia producing rest pain, ischemic digits, or skin ulceration may be differentiated from disease due to CF by appropriate noninvasive testing or imaging of the arterial vasculature. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14486?source=see_link\">",
"     \"Clinical manifestations and evaluation of chronic critical limb ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Atheroemboli",
"    </span>",
"    &nbsp;&mdash;&nbsp;Embolization of atheroma or of cholesterol crystals can result in occlusion of small or medium sized arterial vessels. Atheroembolism may be spontaneous or can be triggered by events such as angiography or apparently inconsequential trauma in the presence of aortic atherosclerosis. Cholesterol clefts may be present in affected vessels when examined histologically. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10809?source=see_link\">",
"     \"Embolism from aortic plaque: Thromboembolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Septic emboli",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arterial embolism from a heart valve or other endovascular infection may produce peripheral ischemia. The presence of fever, a heart murmur, a prosthetic valve or vascular graft, or behavior such as intravenous drug use that increases the risk of endovascular infection should lead to blood cultures. Skin biopsies should be gram stained and cultured for potentially pathogenic organisms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18249?source=see_link\">",
"     \"Complications and outcome of infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Inherited or acquired hypercoagulable states",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low levels of functional protein S, protein, C, and inheritance of mutant forms of other clotting factors (eg, Factor V or prothrombin) are also associated with arterial thrombosis. Acquired disorders that should be considered include thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    induced thrombocytopenia (HIT) (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Thrombocytopenic disorders'",
"    </a>",
"    below), the antiphospholipid syndrome (see",
"    <a class=\"local\" href=\"#H20\">",
"     'Antiphospholipid syndrome'",
"    </a>",
"    below), and hypercoagulability due to malignant disease that is not associated with the presence of CF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=see_link\">",
"     \"Hypercoagulable disorders associated with malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Disseminated intravascular coagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated intravascular coagulation (DIC) due to underlying problems such as infection or malignant disease may present with predominantly thrombotic or thromboembolic phenomena. The presence of bleeding with petechiae, purpura, or ecchymoses is suggestive as is the presence of microangiopathic features on a blood smear. Elevated levels of fibrin degradation products",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    D-dimer are suggestive and prolongation of prothrombin and activated partial thromboplastin time may be seen in acute DIC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Warfarin-induced skin necrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    (coumarin) use sometimes results in skin infarction and should be considered in the differential diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7576/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H39#H39\">",
"     \"Therapeutic use of warfarin\", section on 'Skin necrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Antiphospholipid syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of antiphospholipid antibodies has been associated with both venous and arterial thrombosis, and skin lesions including livedo reticularis and skin ulceration. This disorder should be suspected in patients with systemic lupus erythematosus, otherwise unexplained thromboembolic events, or recurrent fetal loss. Diagnostic testing for anticardiolipin antibodies, anti-beta-2-glycoprotein I antibodies, and lupus anticoagulant activity may help exclude this disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Thrombocytopenic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombotic thrombocytopenic purpura",
"    <span class=\"nowrap\">",
"     (TTP)/hemolytic",
"    </span>",
"    uremic syndrome (HUS) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -induced thrombocytopenia (HIT) are all associated with an increased incidence of arterial thromboembolic phenomena. Thrombocytopenia is a key feature of these disorders that is not seen in primary (essential) cryofibrinogenemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=see_link\">",
"     \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=see_link\">",
"     \"Heparin-induced thrombocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Oxalosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary hyperoxaluria often produces end-stage renal disease and digital ischemia. Symptomatic renal or ureteral calcium oxalate stones occurring early in life are suggestive and elevated excretion of oxalate and glycolate is diagnostic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12154?source=see_link\">",
"     \"Primary hyperoxaluria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Cryoglobulinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin disease due to the presence of circulating CGs is usually due to venulitis (leukocytoclastic vasculitis) and results in palpable purpura. Skin involvement in cryoglobulinemia is generally not confined to the distal portions of the extremities. Arterial disease may develop in patients with CGs, particularly in those with chronic hepatic B or C infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34040?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polyarteritis nodosa\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Calciphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arterial thrombosis with associated skin necrosis may occur in patients with disordered calcium and phosphate metabolism, generally in the setting of end-stage renal disease. Elliptical Skin biopsies or pathology on amputated digits or limbs may reveal characteristic vascular calcification. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15017?source=see_link\">",
"     \"Calciphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Primary cutaneous disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cutaneous appearance of cryofibrinogenemic lesions may mimic other primary dermatologic syndromes, such as:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Urticaria",
"     </li>",
"     <li>",
"      Livedo or livedoid vasculitis",
"     </li>",
"     <li>",
"      Neutrophilic dermatoses",
"     </li>",
"     <li>",
"      Lipodermatosclerosis",
"     </li>",
"     <li>",
"      Panniculitis",
"     </li>",
"     <li>",
"      Idiopathic perniosis (chilblains)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many of these dermatologic conditions have occasionally been associated with cryofibrinogenemia. In such circumstances establishing a single, definitive diagnosis may be difficult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most reliable treatment option for patients with cryofibrinogenemia who have cold-induced events remains avoidance of cold-exposure and other environmental triggers of symptoms (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28200?source=see_link\">",
"     \"Initial treatment of the Raynaud phenomenon\"",
"    </a>",
"    ). Although no published studies have evaluated other non-pharmaceutical interventions, cessation of smoking and avoidance of sympathomimetic agents (including diet pills, decongestants, and caffeine) are advisable to prevent the possible exacerbation of symptoms or precipitation of thromboses due to their vasoconstrictive activities. The roles of biofeedback or other behavioral therapies remain undefined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Primary CF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of primary (essential) cryofibrinogenemia is generally less satisfying than that of secondary cryofibrinogenemia (see",
"    <a class=\"local\" href=\"#H30\">",
"     'Secondary CF'",
"    </a>",
"    below). Treatment approaches are based upon case reports and small case series. Treatments for primary CF that have been employed with reported success include single fibrinolytic, immunosuppressive, and cytotoxic drugs and combinations of such agents. Possible benefit from use of anticoagulants has been reported, but is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Fibrinolytic approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Agents that promote or cause fibrinolysis such as stanozolol, streptokinase, streptodornase, or urokinase have been reported to be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7576/abstract/25,32,36-40\">",
"     25,32,36-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stanozolol &mdash; Oral stanozolol (2 to 4 mg twice daily) has been effective in several case reports [",
"      <a class=\"abstract\" href=\"UTD.htm?7/25/7576/abstract/32,36-40\">",
"       32,36-40",
"      </a>",
"      ]. Several days of treatment may be needed before a beneficial effect is noted, limiting usefulness in acute situations.",
"     </li>",
"     <li>",
"      Streptokinase &mdash; Streptokinase orally (50,000-80,000 units daily) or intravenously (eg, 25,000-200,000 units daily) has a more rapid onset of action than stanozolol. Use of streptokinase in the United States is confined to intravenous administration, limiting its utility as a long-term therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/25/7576/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Immune-based approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunomodulatory approaches, including glucocorticoids, cytotoxic therapy, and plasmapheresis may be of some limited value when used individually [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7576/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Combinations of glucocorticoids and other immunosuppressive agents have also been used. For example, in small studies the combined use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (10-60",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (150",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    were both of benefit, including successful treatment of acute attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7576/abstract/5,35\">",
"     5,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19725056\">",
"    <span class=\"h3\">",
"     Anticoagulant approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Agents that inhibit coagulation, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    in standard therapeutic doses, have also been reported in individual cases to be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7576/abstract/25,43\">",
"     25,43",
"    </a>",
"    ]. However, their use has also been associated with progression of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7576/abstract/5,35\">",
"     5,35",
"    </a>",
"    ]. Thus, some experts do not endorse their routine use [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7576/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Secondary CF",
"    </span>",
"    &nbsp;&mdash;&nbsp;In secondary cryofibrinogenemia, specific treatment of the underlying disease can lead to improvement in CF-related symptoms. Thus, for all patients with CF, age-appropriate malignancy screening and evaluation for possible underlying infection or systemic inflammatory disease are indicated. However, since the prevalence of various malignancies and infections in cryofibrinogenemia remain largely uncharacterized, work-up for underlying conditions should be directed by the patient's clinical presentation.",
"   </p>",
"   <p>",
"    Patients with underlying systemic lupus erythematosus or other connective tissue diseases may respond to glucocorticoids, cytotoxic therapy, or plasmapheresis as dictated by their underlying disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7576/abstract/44-47\">",
"     44-47",
"    </a>",
"    ]; while patients with infections or malignancies may respond to specific antimicrobial therapy or oncologic interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7576/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Outcomes for such approaches, however, are limited to individual or small series case reports, making generalized statements regarding treatment difficult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A person whose plasma, but not serum, forms a cryoprecipitate is referred to as having cryofibrinogenemia.",
"     </li>",
"     <li>",
"      Healthy persons may have demonstrable amounts of cryofibrinogen, but usually less than 50",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Asymptomatic cryofibrinogenemia'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Circulating cryofibrinogen (CF) is also associated with various diseases, physiologic states, and drugs (",
"      <a class=\"graphic graphic_table graphicRef72157 \" href=\"UTD.htm?21/56/22413\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Diagnosis of essential (idiopathic) cryofibrinogenemia requires the presence of CF in plasma, the absence of cryoglobulins, and one or more compatible clinical features (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical manifestations'",
"      </a>",
"      above) such as cold-induced thromboses, increases in blood viscosity",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vascular reactivity, painful ulcers, purpura, livedo reticularis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      painful or pruritic erythema (perniosis) of the extremities or arthralgias (",
"      <a class=\"graphic graphic_table graphicRef81681 \" href=\"UTD.htm?23/36/24139\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Angiographically documented occlusion of small arteries and histologic evidence of thrombosis are also supportive of the diagnosis.",
"     </li>",
"     <li>",
"      Secondary cryofibrinogenemia is diagnosed when an associated disease, physiologic state, or drug is present.",
"     </li>",
"     <li>",
"      The differential diagnosis includes: frostbite and a spectrum of thrombotic, embolic, and vasculopathic disorders (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Differential diagnosis'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Although there are no published studies of nonpharmacologic interventions, we recommend smoking cessation, avoiding cold exposure and eliminating the use of vasoconstricting drugs.",
"     </li>",
"     <li>",
"      We suggest treatment for critical acute ischemia due to cryofibrinogenemia with intravenous streptokinase (25000 to 200000 units daily). An alternative, where available, is oral streptokinase (50000 to 80000 units daily).",
"     </li>",
"     <li>",
"      Oral stanozolol (2 to 4 mg twice daily) is also suggested with recognition that its onset of action is often delayed.",
"     </li>",
"     <li>",
"      Improvement has been noted with use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (10 to 60",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      (150",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      alone or in combination and the use of one or more of these immunosuppressive agents is suggested in patients with associated connective tissue or autoimmune disorders (see",
"      <a class=\"local\" href=\"#H29\">",
"       'Immune-based approaches'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Plasmapheresis might be considered when high levels of CF are present, and are associated with monoclonal proteins (eg, myeloma, Waldenstr&ouml;m&rsquo;s macroglobulinemia), hyperviscosity, or clinically significant thrombosis.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/1\">",
"      KORST DR, KRATOCHVIL CH. Cryofibrinogen in a case of lung neoplasm associated with thrombophlebitis migrans. Blood 1955; 10:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/2\">",
"      Komp DM, Donaldson MH. The relationship between fibrinogen degradation products and cryofibrinogen. Am J Pediatr Hematol Oncol 1979; 1:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/3\">",
"      Stathakis NE, Karamanolis D, Koukoulis G, Tsianos E. Characterization of cryofibrinogen isolated from patients plasma. Haemostasis 1981; 10:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/4\">",
"      Tissot JD, Invernizzi F, Schifferli JA, et al. Two-dimensional electrophoretic analysis of cryoproteins: a report of 335 samples. Electrophoresis 1999; 20:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/5\">",
"      Blain H, Cacoub P, Musset L, et al. Cryofibrinogenaemia: a study of 49 patients. Clin Exp Immunol 2000; 120:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/6\">",
"      Martin S. Cryofibrinogenemia, monoclonal gammopathy, and purpura. Report of a case and review of the literature. Arch Dermatol 1979; 115:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/7\">",
"      Komp DM, Donaldson MH. In vitro and in vivo effects of heparin on cryofibrinogen. N Engl J Med 1968; 279:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/8\">",
"      Stathakis NE, Mosesson MW. Interactions among heparin, cold-insoluble globulin, and fibrinogen in formation of the heparin-precipitable fraction of plasma. J Clin Invest 1977; 60:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/9\">",
"      Hobbs JR. Cryoproteins. Ann Med Interne (Paris) 1986; 137:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/10\">",
"      Kalivas J. Testing for cryofibrinogenemia. J Dermatol Surg Oncol 1979; 5:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/11\">",
"      Sack GH Jr, Levin J, Bell WR. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore) 1977; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/12\">",
"      Belizna CC, Tron F, Joly P, et al. Outcome of essential cryofibrinogenaemia in a series of 61 patients. Rheumatology (Oxford) 2008; 47:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/13\">",
"      Lolin Y, Razis PA, O'Gorman P, et al. Transient nephrotic syndrome after anaesthesia resulting from a familial cryofibrinogen precipitating at 35 degrees C. J Med Genet 1989; 26:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/14\">",
"      Wulffraat N, Meyer KJ, Zegers BJ, Kuis W. Familial presence of primary cryofibrinogenaemia, a report of three cases. Br J Rheumatol 1996; 35:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/15\">",
"      van Geest AJ, van Dooren-Greebe RJ, Andriessen MP, et al. Familial primary cryofibrinogenemia. J Eur Acad Dermatol Venereol 1999; 12:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/16\">",
"      Matsuda M, Saida T, Hasegawa R. Cryofibrinogen in the plasma of patients with skin ulcerative lesions on the legs: a complex of fibrinogen and cold insoluble globulin. Thromb Res 1976; 9:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/17\">",
"      McKee PK, Kalbfleisch JM, Bird RM. Incidence and significance of cryofibrinogenemia. J Lab Clin Med 1963; 61:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/18\">",
"      Zlotnick A, Shahin W, Rachmilewitz EA. Studies in cryofibrinogenemia. Acta Haematol 1969; 42:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/19\">",
"      Smith SB, Arkin C. Cryofibrinogenemia: incidence, clinical correlations, and a review of the literature. Am J Clin Pathol 1972; 58:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/20\">",
"      RITZMANN SE, LEVIN WC, IVERS JB, KOCH JL. I. CRYOPROTEINEMIAS. 2. PRIMARY CRYOFIBRINOGENEMIA--ITS ASSOCIATION WITH CRYOPATHY AND TELANGIECTASIS. Tex Rep Biol Med 1963; 21:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/21\">",
"      Rachmilewitz EA, Sacks MI, Zlotnick A. Essential cryofibrinogenemia. Clinical, pathological and immunological studies. Isr J Med Sci 1970; 6:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/22\">",
"      Ireland TA, Werner DA, Rietschel RL, et al. Cutaneous lesions in cryofibrinogenemia. J Pediatr 1984; 105:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/23\">",
"      Crowson AN, Magro CM. Idiopathic perniosis and its mimics: a clinical and histological study of 38 cases. Hum Pathol 1997; 28:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/24\">",
"      Saadoun D, Elalamy I, Ghillani-Dalbin P, et al. Cryofibrinogenemia: new insights into clinical and pathogenic features. Am J Med 2009; 122:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/25\">",
"      Belizna C, Loufrani L, Subra JF, et al. A 5-year prospective follow-up study in essential cryofibrinogenemia patients. Autoimmun Rev 2011; 10:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/26\">",
"      McGrath MA, Wechsler F, Hunyor AB, Penny R. Systemic factors contributory to retinal vein occlusion. Arch Intern Med 1978; 138:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/27\">",
"      Tsai RK, Chang CH. Central retinal vein occlusion associated with cryofibrinogenemia in a young adult--study of skin dynamic capillaroscopy. J Formos Med Assoc 1998; 97:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/28\">",
"      Dunsker SB, Torres-Reyes E, Peden JC Jr. Pseudotumor cerebri associated with idiopathic cryofibrinogenemia. Report of a case. Arch Neurol 1970; 23:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/29\">",
"      Lin RY, Janniger CK, Schwartz RA, Lambert WC. Cold urticaria. Am Fam Physician 1986; 33:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/30\">",
"      Orfan N, Marhoul J, Lerner C, Lawrence ID. Systemic cold urticaria in a five-year-old boy. Ann Allergy 1991; 67:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/31\">",
"      Delluc A, Saadoun D, Ghillani-Dalbin P, et al. Cryofibrinogen in patients with hepatitis C virus infection. Am J Med 2008; 121:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/32\">",
"      Jantunen E, Soppi E, Neittaanm&auml;ki H, Lahtinen R. Essential cryofibrinogenaemia, leukocytoclastic vasculitis and chronic purpura. J Intern Med 1993; 234:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/33\">",
"      Nash JW, Ross P Jr, Neil Crowson A, et al. The histopathologic spectrum of cryofibrinogenemia in four anatomic sites. Skin, lung, muscle, and kidney. Am J Clin Pathol 2003; 119:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/34\">",
"      Euler HH, Zeuner RA, B&eacute;ress R, et al. Monoclonal cryo-antifibrinogenemia. Arthritis Rheum 1996; 39:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/35\">",
"      Amdo TD, Welker JA. An approach to the diagnosis and treatment of cryofibrinogenemia. Am J Med 2004; 116:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/36\">",
"      Falanga V, Kirsner RS, Eaglstein WH, et al. Stanozolol in treatment of leg ulcers due to cryofibrinogenaemia. Lancet 1991; 338:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/37\">",
"      Klein AD, Kerdel FA. Purpura and recurrent ulcers on the lower extremities. Essential cryofibrinogenemia. Arch Dermatol 1991; 127:115, 118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/38\">",
"      Kirsner RS, Eaglstein WH, Katz MH, et al. Stanozolol causes rapid pain relief and healing of cutaneous ulcers caused by cryofibrinogenemia. J Am Acad Dermatol 1993; 28:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/39\">",
"      Helfman T, Falanga V. Stanozolol as a novel therapeutic agent in dermatology. J Am Acad Dermatol 1995; 33:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/40\">",
"      Rubegni P, Flori ML, Fimiani M, Andreassi L. A case of cryofibrinogenaemia responsive to stanozolol. Br J Haematol 1996; 93:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/41\">",
"      Sankarasubbaiyan S, Scott G, Holley JL. Cryofibrinogenemia: an addition to the differential diagnosis of calciphylaxis in end-stage renal disease. Am J Kidney Dis 1998; 32:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/42\">",
"      Siami GA, Siami FS. Plasmapheresis and paraproteinemia: cryoprotein-induced diseases, monoclonal gammopathy, Waldenstr&ouml;m's macroglobulinemia, hyperviscosity syndrome, multiple myeloma, light chain disease, and amyloidosis. Ther Apher 1999; 3:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/43\">",
"      Browning CE, Callen JP. Warfarin therapy for livedoid vasculopathy associated with cryofibrinogenemia and hyperhomocysteinemia. Arch Dermatol 2006; 142:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/44\">",
"      Copeman PW. Cryofibrinogenaemia and skin ulcers: treatment with plasmapheresis. Br J Dermatol 1979; 101 Suppl 17:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/45\">",
"      Siami FS, Siami GA. Cryofiltration apheresis in the treatment of cryoprecipitate induced diseases. Ther Apher 1997; 1:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/46\">",
"      Bair JS, Wu YC, L&uuml; YC. Cryofibrinogenemia: report of a case. J Formos Med Assoc 1991; 90:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/47\">",
"      Young GD, Cleland LG, McNeil JD. Cryofibrinogenaemia: a case report. Aust N Z J Med 1991; 21:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/48\">",
"      Lazar AP, Lazar P. Giardiasis, cryofibrinogenemia, and cold sensitivity: a response to metronidazole. Int J Dermatol 1991; 30:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7576/abstract/49\">",
"      Stavem P, R&oslash;rvik T, Brandtzaeg P, et al. Gastric lymphoma causing granulocytopenia and cold intolerance, with recovery after treatment. J Intern Med 1991; 229:193.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1819 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3548BCC041-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_25_7576=[""].join("\n");
var outline_f7_25_7576=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Cryoprecipitates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Cryoglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Cryofibrinogenemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MEASUREMENT OF CRYOFIBRINOGEN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL SIGNIFICANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Asymptomatic cryofibrinogenemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Frostbite",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Atherosclerotic peripheral vascular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Atheroemboli",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Septic emboli",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Inherited or acquired hypercoagulable states",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Disseminated intravascular coagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Warfarin-induced skin necrosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Thrombocytopenic disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Oxalosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Cryoglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Calciphylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Primary cutaneous disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Primary CF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Fibrinolytic approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Immune-based approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19725056\">",
"      - Anticoagulant approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Secondary CF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/1819\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1819|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/56/22413\" title=\"table 1\">",
"      Cryofibrinogen associations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/36/24139\" title=\"table 2\">",
"      Cryofibrinogen manifestations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15017?source=related_link\">",
"      Calciphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=related_link\">",
"      Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=related_link\">",
"      Clinical manifestations and diagnosis of polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34040?source=related_link\">",
"      Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14486?source=related_link\">",
"      Clinical manifestations and evaluation of chronic critical limb ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18249?source=related_link\">",
"      Complications and outcome of infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=related_link\">",
"      Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10809?source=related_link\">",
"      Embolism from aortic plaque: Thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37671?source=related_link\">",
"      Frostbite",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=related_link\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=related_link\">",
"      Hypercoagulable disorders associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28200?source=related_link\">",
"      Initial treatment of the Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12154?source=related_link\">",
"      Primary hyperoxaluria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36682?source=related_link\">",
"      Treatment of the mixed cryoglobulinemia syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27400?source=related_link\">",
"      Types of renal disease in multiple myeloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_25_7577="Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients";
var content_f7_25_7577=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/25/7577/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/25/7577/contributors\">",
"     Patricia A Tietjen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/25/7577/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/25/7577/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/25/7577/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/25/7577/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/25/7577/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumocystis was identified by Carlos Chagas, who originally thought that this organism was part of the life cycle of Trypanosoma cruzi; Pneumocystis was not recognized as a unique organism until 1912 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/1\">",
"     1",
"    </a>",
"    ]. As the use of immunosuppressive therapy became more common, clinicians began to recognize this organism as a cause of life-threatening pneumonia. However, its prominence as an opportunistic infection didn't emerge until the beginning of the AIDS epidemic, when pneumocystis pneumonia (PCP, officially renamed Pneumocystis jirovecii pneumonia) was reported in the initial case reports of pneumonia in men who have sex with men (MSM). Prior to 1981, there were fewer than one hundred cases of pneumocystis infection reported annually in the United States, mainly in patients with malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of pneumocystis pneumonia in HIV-infected patients in developed countries has greatly decreased since approximately 1988. This reduction resulted both from recommendations for primary prophylaxis against the infection in patients with CD4 cell counts",
"    <span class=\"nowrap\">",
"     &lt;200/microL",
"    </span>",
"    and widespread adoption of potent antiretroviral therapy (ART) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/3-7\">",
"     3-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The general features of pneumocystis pneumonia in the HIV-infected patient, including clinical presentation and diagnosis, will be reviewed here. Treatment and prophylaxis of pneumocystis infection are considered elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27593?source=see_link\">",
"     \"Treatment of Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2889?source=see_link\">",
"     \"Prophylaxis against Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1429656\">",
"    <span class=\"h1\">",
"     TAXONOMY AND TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The taxonomic classification of pneumocystis as a genus of protozoan organisms was questioned for several years. Now they are recognized as fungi based on ribosomal RNA and other gene sequence homologies, the composition of their cell walls, and the structure of key enzymes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The nomenclature for the organism demonstrates the diversity of the Pneumocystis genus [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/9\">",
"     9",
"    </a>",
"    ]. Four species have been described: two species that infect rats, including P. carinii; and one that infects humans, P. jirovecii [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/10\">",
"     10",
"    </a>",
"    ]. P. jirovecii has been designated as the species name to use in future publications and references to human infections [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. However, the abbreviation of &ldquo;PCP&rdquo; is still used in the infectious disease community to refer to the clinical entity of &ldquo;PneumoCystis Pneumonia&rdquo;; this allows for the retention of the familiar acronym amongst clinicians and maintains the accuracy of this abbreviation in older published papers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the organism was first identified in the lungs of guinea pigs by Chagas and then Carinii in the early 1900s, the first cases of active pneumonitis in humans were recognized in premature and malnourished children in Europe during World War II. The organism was originally believed to be a protozoan because of its three morphologic forms. These forms include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cysts, which are round or crescent shaped, five to eight microns in diameter, and covered by a three-layer pellicle.",
"     </li>",
"     <li>",
"      Sporozoites, which are present within the cysts. The mature cyst can contain up to eight sporozoites, which are round or crescent-shaped intracystic structures one to two microns in diameter.",
"     </li>",
"     <li>",
"      Trophozoites, which are the free-floating forms of Pneumocystis. They are two to five microns in size and pleomorphic. They tend to form clusters and resemble platelets.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Antigenic variability",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most abundant surface protein of Pneumocystis is the major surface glycoprotein (MSG) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/12\">",
"     12",
"    </a>",
"    ]. Variation of the expressed MSG may facilitate evasion of host immune responses. One study demonstrated that increased diversity in the MSG repertoire was generated in part by recombination [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary mode of transmission of P. jirovecii is uncertain. Common teaching used to be that the organism was transmitted early in life by the respiratory-aerosol route, with 75 percent of humans infected by the age of four years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/14\">",
"     14",
"    </a>",
"    ]. These primary infections were presumed to be asymptomatic, and the organism was believed to remain in a latent state unless the patient became immunosuppressed.",
"   </p>",
"   <p>",
"    However, this theory of latency has come under question. Experiments in rats, mice with severe combined immunodeficiency (SCID), and macaques infected with simian immunodeficiency virus (SIV) all show that these hosts are capable of clearing the organism [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]; transmission among macaques also appeared to occur. Asymptomatic carriage of the organism also does not appear to be as common as previously thought [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/18\">",
"     18",
"    </a>",
"    ]. While carriers may be agents for airborne transmission of the organism, reinfection with different genotypes probably occurs with as much regularity as reactivation of endogenous organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While reports of cluster outbreaks in oncology units and among HIV-infected patients suggest that human-to-human transmission is possible, genotypic analyses indicate that acquisition of infection in such a manner is relatively infrequent and accounts for a minority of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. When cases of PCP among HIV-infected patients are retrospectively analyzed by geographic location, clustering by zip code has been demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. A study of air sampling near 19 patients with Pneumocystis infection demonstrated the detection of P. jirovecii DNA in 80 percent of samples at a distance of one meter [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/25\">",
"     25",
"    </a>",
"    ]. These data raise, but do not confirm, the possibility of a common environmental exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Colonization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumocystis may be present in the respiratory tract when clinical pneumonia is absent. In such colonized individuals, Pneumocystis is usually identified through the use of polymerase chain reaction assays. Pneumocystis has also been demonstrated to be a common colonizer in hospitalized patients with bacterial and viral pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/26\">",
"     26",
"    </a>",
"    ]. The clinical significance of colonization is not well understood, but may be important for several reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Colonized individuals may be at risk of developing pneumonia or transmitting infection.",
"     </li>",
"     <li>",
"      Colonized individuals receiving Pneumocystis prophylaxis may be at risk for developing drug resistance mutations.",
"     </li>",
"     <li>",
"      Ongoing colonization may trigger inflammation and local alveolar damage leading to lung diseases, such as chronic obstructive pulmonary disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the era of potent ART, it was observed that the incidence of PCP in HIV-infected patients increased as the CD4 count decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/3,28,29\">",
"     3,28,29",
"    </a>",
"    ]. Generally, PCP did not occur until the CD4 count dropped below 200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    In the multicenter AIDS Cohort Study, for example, the incidence of PCP with a CD4 count of 201 to 350",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    was 0.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/30\">",
"     30",
"    </a>",
"    ]. However, within six months of the CD4 count falling below 200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ,",
"    </span>",
"    8 percent of patients developed PCP.",
"   </p>",
"   <p>",
"    In a study of more than 1100 individuals with HIV infection, the Pulmonary Complications of HIV Infection Study Group confirmed the relationship between CD4 cell count and PCP [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/28\">",
"     28",
"    </a>",
"    ]. Ninety-five percent of patients who developed PCP had a CD4 count below 200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    HIV transmission category, age, smoking history, and use of antiretroviral therapy did not predict development of PCP; black subjects had one-third the risk of PCP compared to white patients.",
"   </p>",
"   <p>",
"    Several studies demonstrated that the incidence of PCP declined significantly after recommendations for PCP prophylaxis and potent ART were initiated [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/3,5,6\">",
"     3,5,6",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies highlight that mortality rates are declining in patients with PCP. One United States-based study of trends in AIDS-associated PCP hospital discharges between 1986 and 2005 showed that mortality had declined from 21 to 7 percent with the introduction of prophylaxis and potent ART [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/31\">",
"     31",
"    </a>",
"    ]. However, in other studies, PCP has remained the leading cause of death among those not receiving or failing to comply with ART or PCP prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/7,32\">",
"     7,32",
"    </a>",
"    ]. Predictors of mortality include older age, recent injection drug use, increased total bilirubin, low serum albumin, and an alveolar-arterial oxygen gradient &ge;50 mm Hg [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Worsening of PCP after immune reconstitution due to ART has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link&amp;anchor=H13#H13\">",
"     \"Immune reconstitution inflammatory syndrome\", section on 'IRIS associated with Pneumocystis jirovecii infection'",
"    </a>",
"    .) .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Clinical symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;In HIV-infected patients, PCP is generally gradual in onset and characterized by fever (79 to 100 percent), cough (95 percent), and progressive dyspnea (95 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/37\">",
"     37",
"    </a>",
"    ]. The cough is generally nonproductive, but as many as 30 percent of patients may have some sputum production.",
"   </p>",
"   <p>",
"    Other symptoms include fatigue, chills, chest pain, and weight loss. Approximately 7 percent of patients are asymptomatic. Although fewer patients are receiving aerosolized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    as PCP prophylaxis, atypical manifestations and extrapulmonary PCP are considerations in those receiving this agent.",
"   </p>",
"   <p>",
"    Uncommon extrapulmonary manifestations include lesions within the liver, spleen, kidney, and brain, especially in patients taking non-systemic prophylaxis (eg, aerosolized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common findings on physical examination are fever (84 percent of patients have a temperature exceeding 38.1&ordm;C) and tachypnea (62 percent). The most common adventitial sounds are crackles and rhonchi, but a normal chest examination occurs in 50 percent of cases. Extrapulmonary manifestations of P. carinii infection, such as hepatosplenomegaly, skin lesions, and pleural effusions, can be seen in patients receiving localized PCP prophylaxis with aerosolized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest radiographs are initially normal in up to one-fourth of patients with PCP. The most common radiographic abnormalities are diffuse, bilateral, interstitial, or alveolar infiltrates [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/39\">",
"     39",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61559 \" href=\"UTD.htm?24/0/24580\">",
"     image 1",
"    </a>",
"    ). Although upper lobe infiltrates can be seen de novo, a higher incidence of predominantly apical infiltrates is reported in patients using aerosolized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/40\">",
"     40",
"    </a>",
"    ]. Other, less common presentations include [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/37,41\">",
"     37,41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pneumothoraces (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20678?source=see_link\">",
"       \"Pneumothorax in HIV-infected patients\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lobar or segmental infiltrates",
"     </li>",
"     <li>",
"      Cysts",
"     </li>",
"     <li>",
"      Nodules",
"     </li>",
"     <li>",
"      Pleural effusions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    High resolution computed tomography (HRCT) has a high sensitivity for PCP among HIV-positive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. One study, for example, evaluated 51 patients with suspected PCP and normal, equivocal, or nonspecific chest x-ray findings; HRCT had a sensitivity of 100 percent and a specificity of 89 percent when the presence of patchy or nodular ground-glass attenuation was used to indicate possible PCP [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/43\">",
"     43",
"    </a>",
"    ]. While such findings are suggestive, they are not diagnostic. However, a negative high resolution computed tomography scan makes the diagnosis of PCP highly unlikely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     OTHER LABORATORY STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gallium-67 citrate scanning is a highly sensitive test in patients with PCP, demonstrating intense, diffuse bilateral uptake [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/45\">",
"     45",
"    </a>",
"    ]. However, its role is limited by lack of specificity, its high cost, and a two-day delay in obtaining final results. Nevertheless, it may have some usefulness as a screening test when there is a question of active pulmonary infection, especially in patients with normal chest radiographs.",
"   </p>",
"   <p>",
"    Other screening tests for PCP include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measurement of the diffusing capacity for carbon monoxide (DLCO). PCP is highly unlikely if the DLCO is normal, defined by 70 percent of the predicted value or greater. As an example, one prospective study of 306 HIV-positive patients with 467 episodes of worsening respiratory symptoms found that PCP pneumonia was present in less than 2 percent of patients with a normal or unchanged chest x-ray and a single breath DLCO &gt;75 percent of the predicted value [",
"      <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Assessment of oxygenation at rest and with exercise [",
"      <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/47\">",
"       47",
"      </a>",
"      ]. The presence of PCP is highly unlikely if the response to exercise is normal, ie, a decrease in the alveolar-arterial oxygen gradient or an increase in the oxygen saturation with exercise.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The two most common abnormal laboratory values associated with PCP in HIV-infected patients are a CD4 count below 200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    and an elevated lactate dehydrogenase level (LDH) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/30,48,49\">",
"     30,48,49",
"    </a>",
"    ]. The latter is present in 90 percent of HIV-infected patients with PCP and has some prognostic significance. In one study, for example, the mean LDH of PCP survivors was 340 IU, while the mean level of non-survivors was 447 IU [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/48\">",
"     48",
"    </a>",
"    ]. More importantly, a rising LDH level despite appropriate treatment portends a poor prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     USE OF EMPIRIC THERAPY FOR PCP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some clinicians advocate empiric treatment for PCP in high-risk patients. One study investigated the relationship between health care coverage and diagnostic procedures in HIV-infected patients with PCP, and correlated these factors to patient outcome. Medicaid patients were more likely to be empirically treated for PCP and also were more likely to die in-hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/50\">",
"     50",
"    </a>",
"    ]. The higher mortality in this group may have been due to a failure to diagnose pathogens other than P. jirovecii, because procedures that could make a specific diagnosis were less likely to be performed in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Establishing a definitive diagnosis of PCP is usually recommended for two reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With ART and PCP prophylaxis, PCP is less common (as long as patients are compliant) and may have atypical presentations.",
"     </li>",
"     <li>",
"      Therapy may be toxic or even contraindicated (eg, the use of steroids in patients presumed to have PCP but actually infected with Mycobacterium tuberculosis).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DEFINITIVE DIAGNOSIS OF PCP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific diagnosis of PCP requires documentation of the organism in respiratory specimens. Conventional stains such as toluidine blue O, Grocott's",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/57/3989?source=see_link\">",
"     methenamine",
"    </a>",
"    silver, or Giemsa can be used to identify the organism. Immunofluorescent staining is the most common and sensitive technique currently in use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Sputum induction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most rapid and least invasive method of diagnosing PCP is by analysis of sputum induced by the inhalation of hypertonic saline. While the specificity of this method approaches 100 percent, the sensitivity ranges from 55 to 92 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. This variability is related to the prevalence of PCP in the patient population, the skill of the team inducing the sputum, and the expertise of the laboratory processing and interpreting the specimen.",
"   </p>",
"   <p>",
"    PCP prophylaxis, especially with aerosolized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    , seems to lower the diagnostic sensitivity of sputum induction. In one study, for example, the yield of sputum induction in patients not receiving prophylaxis was 92 percent, compared with 64 percent in patients receiving aerosolized pentamidine prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/54\">",
"     54",
"    </a>",
"    ]. The specificity of a positive induced sputum is reduced following an acute episode of PCP because visible organisms may persist in the sputa of successfully treated patients. One series of 24 patients found residual cysts in 16 (76 percent) after the completion of three weeks of appropriate antimicrobial therapy, but this finding was not associated with an increased risk of relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/55\">",
"     55",
"    </a>",
"    ]. Three weeks later, 24 percent of all patients still had positive induced sputa.",
"   </p>",
"   <p>",
"    Immunofluorescent staining, using monoclonal antibodies against glycoproteins in the cell walls of the cysts and trophozoites of P. carinii, may increase the yield of sputum induction. One report showed that when antibody-staining techniques were applied to induced sputum, the sensitivity for PCP was 95 percent and the specificity was 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Bronchoalveolar lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;If sputum induction is nondiagnostic or cannot be performed (eg, the patient cannot cooperate, is too dyspneic, or has an altered mental status), then fiberoptic bronchoscopy with bronchoalveolar lavage (BAL) is recommended, with or without transbronchial biopsy. BAL alone has a diagnostic yield of 97 to 100 percent in HIV-infected patients. However, it has been suggested that the diagnostic sensitivity of BAL in patients using aerosolized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    prophylaxis may be as low as 62 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/40\">",
"     40",
"    </a>",
"    ]. In these patients, transbronchial biopsy, which has a diagnostic yield of up to 100 percent, can be added.",
"   </p>",
"   <p>",
"    Site-directed lavage, which involves sampling the most heavily involved lobes on chest radiograph, can also increase the yield in patients with focal infiltrates. One group has shown that the combination of site-directed lavage and immunofluorescent antibody staining increased the sensitivity of BAL from 80 to 98 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major complications of BAL include respiratory failure (rare) and fever (common). Transbronchial biopsy can be complicated by hemoptysis and pneumothorax (the latter occurring in less than 2 percent). Of note, BAL can be done without a bronchoscope by introducing a BAL catheter blindly into the lung [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/58\">",
"     58",
"    </a>",
"    ]. The diagnostic yield is similar to that of BAL, but it is rarely used since most physicians are unfamiliar with the technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26350715\">",
"    <span class=\"h2\">",
"     Serum 1-3-beta-D-glucan",
"    </span>",
"    &nbsp;&mdash;&nbsp;The test characteristics of serum 1-3-beta-D-glucan were evaluated for the diagnosis of PCP among 282 patients who were enrolled in a trial to evaluate the timing of ART relative to treatment of various opportunistic infections [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/59\">",
"     59",
"    </a>",
"    ]. Baseline plasma samples were assayed for beta-D-glucan in all patients, with standard positive assay reference values defined as &gt;80",
"    <span class=\"nowrap\">",
"     pg/mL.",
"    </span>",
"    Patients with a diagnosis of PCP had higher median beta-D-glucan levels than those who did not have PCP (408",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    versus 37",
"    <span class=\"nowrap\">",
"     pg/mL).",
"    </span>",
"    The sensitivity of beta-D-glucan for the diagnosis of PCP was 92 percent and the specificity was 65 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Other procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of PCP can sometimes be made through use of endotracheal aspirates of via transthoracic needle biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26350701\">",
"    <span class=\"h3\">",
"     Endotracheal aspirates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endotracheal aspirates from intubated and mechanically ventilated patients appear to have a high sensitivity for the detection of PCP. As an example, one study of 31 intubated patients found that endotracheal aspirates examined with immunostaining techniques had a sensitivity of 92 percent for PCP, with immunostained BAL specimens serving as the reference standard [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/60\">",
"     60",
"    </a>",
"    ]. Thus, examination of endotracheal aspirates in intubated patients may obviate the need for bronchoscopy in many cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26350708\">",
"    <span class=\"h3\">",
"     Transthoracic needle biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transthoracic needle biopsy, which has a high diagnostic yield, is rarely used because of the 30 percent incidence of pneumothorax. Although lung biopsy, either by thoracotomy or by video-assisted thoracoscopic surgery, can be performed with an assurance of 100 percent sensitivity and specificity for the diagnosis of PCP, it is used very infrequently because of its cost and invasiveness and because the diagnosis is usually made with less invasive procedures. Histology on lung biopsy demonstrates the formation of a foamy, eosinophilic alveolar exudate; severe cases are associated with edema and interstitial fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Diagnosis of PCP in patients on prophylactic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of breakthrough PCP (ie, PCP occurring despite adequate prophylaxis) may be more complicated than that of PCP occurring without prophylaxis. The problems associated with breakthrough PCP have been closely examined in patients receiving aerosolized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    prophylaxis, but no good data exist for patients receiving systemic prophylaxis. In breakthrough PCP, the clinical course may be less severe, the radiographic findings may be atypical, and the diagnostic yield of traditional BAL (ie, from the lingula and right middle lobe) may be lower, as noted above [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also evidence that higher rates of pneumothorax may be seen in patients on aerosolized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20678?source=see_link\">",
"     \"Pneumothorax in HIV-infected patients\"",
"    </a>",
"    .) One study found that cigarette smoking, active PCP, the presence of pneumatoceles on chest radiographs, and aerosolized pentamidine prophylaxis were risk factors for the development of pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/62\">",
"     62",
"    </a>",
"    ]. Because the presence of PCP correlates so closely with the development of pneumothorax, all HIV-infected patients who develop a pneumothorax should be investigated for the presence of Pneumocystis carinii.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The application of polymerase chain reaction (PCR) technology to the diagnosis of PCP is actively under investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/2,63\">",
"     2,63",
"    </a>",
"    ]. In addition to making a diagnosis, PCR-based testing could allow quantitation of the organism in the attempt to differentiate colonization from infection and could be used to detect drug resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One small study showed that circulating Pneumocystis DNA was present in the blood of 86 percent of patients with active PCP but none of the HIV-infected patients without pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/66\">",
"     66",
"    </a>",
"    ]. Studies looking at the diagnostic utility of PCR in diagnosing Pneumocystis from sputum and BAL specimens have yielded sensitivities ranging from 81 to 100 percent and specificities of 86 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. Another group evaluated PCR on nasopharyngeal samples (nasal or throat swabs or saliva) in AIDS patients with pulmonary infections and controls [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/70\">",
"     70",
"    </a>",
"    ]. Eleven AIDS patients had PCP diagnosed by BAL and PCR was positive in all of these; none of 31 patients with AIDS or cancer who had negative BALs were positive by PCR. In addition, 258 samples from 86 control patients without pneumonia and with AIDS, cancer, or no underlying disease were all negative for PCP by PCR.",
"   </p>",
"   <p>",
"    Although these data look promising, the clinical impact may be small, because other methods of diagnosis have such high yields. Additionally, PCR is not readily available and its cost is high. One approach to diagnosing PCP may be to use conventional staining first and apply PCR or immunofluorescent staining only to the negative samples. Another possible approach is to use PCR on oral washes or gargles as an initial screening test since this has a sensitivity of approximately 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7577/abstract/63\">",
"     63",
"    </a>",
"    ]. However, caution is advised since false positives have been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/24/7554?source=see_link\">",
"       \"Patient information: Pneumocystis pneumonia (PCP) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While PCP is decreasing in frequency due to the use of PCP prophylaxis and ART, it is still the most common OI in HIV-infected patients.",
"     </li>",
"     <li>",
"      PCP can be suspected based upon clinical and radiologic findings but it is preferable to confirm the diagnosis.",
"     </li>",
"     <li>",
"      Empiric therapy for PCP should be started while diagnostic studies are pending.",
"     </li>",
"     <li>",
"      Immunofluorescent staining of specimens obtained by sputum induction is the usual means of making a diagnosis.",
"     </li>",
"     <li>",
"      Bronchoalveolar lavage should be performed if induced sputum is negative.",
"     </li>",
"     <li>",
"      It is uncommon to require lung tissue to diagnose PCP in HIV-infected patients.",
"     </li>",
"     <li>",
"      PCR-based testing can be considered but is not in widespread use.",
"     </li>",
"     <li>",
"      Blood 1,3 beta-Dglucan is a sensitive but non-specific marker of PCP.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/1\">",
"      Kovacs JA, Masur H. Evolving health effects of Pneumocystis: one hundred years of progress in diagnosis and treatment. JAMA 2009; 301:2578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/2\">",
"      Kovacs JA, Gill VJ, Meshnick S, Masur H. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. JAMA 2001; 286:2450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/3\">",
"      Hoover DR, Saah AJ, Bacellar H, et al. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study. N Engl J Med 1993; 329:1922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/4\">",
"      Sepkowitz KA. Effect of prophylaxis on the clinical manifestations of AIDS-related opportunistic infections. Clin Infect Dis 1998; 26:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/5\">",
"      Wolff AJ, O'Donnell AE. Pulmonary manifestations of HIV infection in the era of highly active antiretroviral therapy. Chest 2001; 120:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/6\">",
"      San-Andr&eacute;s FJ, Rubio R, Castilla J, et al. Incidence of acquired immunodeficiency syndrome-associated opportunistic diseases and the effect of treatment on a cohort of 1115 patients infected with human immunodeficiency virus, 1989-1997. Clin Infect Dis 2003; 36:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/7\">",
"      Jain MK, Skiest DJ, Cloud JW, et al. Changes in mortality related to human immunodeficiency virus infection: comparative analysis of inpatient deaths in 1995 and in 1999-2000. Clin Infect Dis 2003; 36:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/8\">",
"      Edman JC, Kovacs JA, Masur H, et al. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature 1988; 334:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/9\">",
"      Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis 2002; 8:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/10\">",
"      Cushion MT, Stringer JR. Has the name really been changed? It has for most researchers. Clin Infect Dis 2005; 41:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/11\">",
"      Gigliotti F. Pneumocystis carinii: has the name really been changed? Clin Infect Dis 2005; 41:1752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/12\">",
"      Stringer JR, Keely SP. Genetics of surface antigen expression in Pneumocystis carinii. Infect Immun 2001; 69:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/13\">",
"      Kutty G, Maldarelli F, Achaz G, Kovacs JA. Variation in the major surface glycoprotein genes in Pneumocystis jirovecii. J Infect Dis 2008; 198:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/14\">",
"      Pifer LL, Hughes WT, Stagno S, Woods D. Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children. Pediatrics 1978; 61:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/15\">",
"      Vargas SL, Hughes WT, Wakefield AE, Oz HS. Limited persistence in and subsequent elimination of Pneumocystis carinii from the lungs after P. carinii pneumonia. J Infect Dis 1995; 172:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/16\">",
"      Chen W, Gigliotti F, Harmsen AG. Latency is not an inevitable outcome of infection with Pneumocystis carinii. Infect Immun 1993; 61:5406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/17\">",
"      Vogel P, Miller CJ, Lowenstine LL, Lackner AA. Evidence of horizontal transmission of Pneumocystis carinii pneumonia in simian immunodeficiency virus-infected rhesus macaques. J Infect Dis 1993; 168:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/18\">",
"      Wakefield AE, Lindley AR, Ambrose HE, et al. Limited asymptomatic carriage of Pneumocystis jiroveci in human immunodeficiency virus-infected patients. J Infect Dis 2003; 187:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/19\">",
"      Singer C, Armstrong D, Rosen PP, Schottenfeld D. Pneumocystis carinii pneumonia: a cluster of eleven cases. Ann Intern Med 1975; 82:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/20\">",
"      Helweg-Larsen J, Tsolaki AG, Miller RF, et al. Clusters of Pneumocystis carinii pneumonia: analysis of person-to-person transmission by genotyping. QJM 1998; 91:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/21\">",
"      Manoloff ES, Francioli P, Taff&eacute; P, et al. Risk for Pneumocystis carinii transmission among patients with pneumonia: a molecular epidemiology study. Emerg Infect Dis 2003; 9:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/22\">",
"      McNally LM, Jeena PM, Lalloo U, et al. Probable mother to infant transmission of Pneumocystis jiroveci from an HIV-infected woman to her HIV-uninfected infant. AIDS 2005; 19:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/23\">",
"      Dohn MN, White ML, Vigdorth EM, et al. Geographic clustering of Pneumocystis carinii pneumonia in patients with HIV infection. Am J Respir Crit Care Med 2000; 162:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/24\">",
"      Morris AM, Swanson M, Ha H, Huang L. Geographic distribution of human immunodeficiency virus-associated Pneumocystis carinii pneumonia in San Francisco. Am J Respir Crit Care Med 2000; 162:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/25\">",
"      Choukri F, Menotti J, Sarfati C, et al. Quantification and spread of Pneumocystis jirovecii in the surrounding air of patients with Pneumocystis pneumonia. Clin Infect Dis 2010; 51:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/26\">",
"      Davis JL, Welsh DA, Beard CB, et al. Pneumocystis colonisation is common among hospitalised HIV infected patients with non-Pneumocystis pneumonia. Thorax 2008; 63:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/27\">",
"      Morris A, Wei K, Afshar K, Huang L. Epidemiology and clinical significance of pneumocystis colonization. J Infect Dis 2008; 197:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/28\">",
"      Stansell JD, Osmond DH, Charlebois E, et al. Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 1997; 155:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/29\">",
"      Bozzette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 1995; 332:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/30\">",
"      Phair J, Mu&ntilde;oz A, Detels R, et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med 1990; 322:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/31\">",
"      Kelley CF, Checkley W, Mannino DM, et al. Trends in hospitalizations for AIDS-associated Pneumocystis jirovecii Pneumonia in the United States (1986 to 2005). Chest 2009; 136:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/32\">",
"      Pulvirenti J, Herrera P, Venkataraman P, Ahmed N. Pneumocystis carinii pneumonia in HIV-infected patients in the HAART era. AIDS Patient Care STDS 2003; 17:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/33\">",
"      Fei MW, Kim EJ, Sant CA, et al. Predicting mortality from HIV-associated Pneumocystis pneumonia at illness presentation: an observational cohort study. Thorax 2009; 64:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/34\">",
"      Crothers K, Huang L. Recurrence of Pneumocystis carinii pneumonia in an HIV-infected patient: apparent selective immune reconstitution after initiation of antiretroviral therapy. HIV Med 2003; 4:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/35\">",
"      Wolff AJ, O'Donnell AE. HIV-related pulmonary infections: a review of the recent literature. Curr Opin Pulm Med 2003; 9:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/36\">",
"      Koval CE, Gigliotti F, Nevins D, Demeter LM. Immune reconstitution syndrome after successful treatment of Pneumocystis carinii pneumonia in a man with human immunodeficiency virus type 1 infection. Clin Infect Dis 2002; 35:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/37\">",
"      Kales CP, Murren JR, Torres RA, Crocco JA. Early predictors of in-hospital mortality for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Arch Intern Med 1987; 147:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/38\">",
"      Ng VL, Yajko DM, Hadley WK. Extrapulmonary pneumocystosis. Clin Microbiol Rev 1997; 10:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/39\">",
"      DeLorenzo LJ, Huang CT, Maguire GP, Stone DJ. Roentgenographic patterns of Pneumocystis carinii pneumonia in 104 patients with AIDS. Chest 1987; 91:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/40\">",
"      Jules-Elysee KM, Stover DE, Zaman MB, et al. Aerosolized pentamidine: effect on diagnosis and presentation of Pneumocystis carinii pneumonia. Ann Intern Med 1990; 112:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/41\">",
"      Sepkowitz KA, Telzak EE, Gold JW, et al. Pneumothorax in AIDS. Ann Intern Med 1991; 114:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/42\">",
"      Gruden JF, Huang L, Turner J, et al. High-resolution CT in the evaluation of clinically suspected Pneumocystis carinii pneumonia in AIDS patients with normal, equivocal, or nonspecific radiographic findings. AJR Am J Roentgenol 1997; 169:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/43\">",
"      Hartman TE, Primack SL, M&uuml;ller NL, Staples CA. Diagnosis of thoracic complications in AIDS: accuracy of CT. AJR Am J Roentgenol 1994; 162:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/44\">",
"      Hidalgo A, Falc&oacute; V, Maule&oacute;n S, et al. Accuracy of high-resolution CT in distinguishing between Pneumocystis carinii pneumonia and non- Pneumocystis carinii pneumonia in AIDS patients. Eur Radiol 2003; 13:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/45\">",
"      Tuazon CU, Delaney MD, Simon GL, et al. Utility of gallium67 scintigraphy and bronchial washings in the diagnosis and treatment of Pneumocystis carinii pneumonia in patients with the acquired immune deficiency syndrome. Am Rev Respir Dis 1985; 132:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/46\">",
"      Huang L, Stansell J, Osmond D, et al. Performance of an algorithm to detect Pneumocystis carinii pneumonia in symptomatic HIV-infected persons. Pulmonary Complications of HIV Infection Study Group. Chest 1999; 115:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/47\">",
"      Stover DE, Meduri GU. Pulmonary function tests. Clin Chest Med 1988; 9:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/48\">",
"      Zaman MK, White DA. Serum lactate dehydrogenase levels and Pneumocystis carinii pneumonia. Diagnostic and prognostic significance. Am Rev Respir Dis 1988; 137:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/49\">",
"      Butt AA, Michaels S, Kissinger P. The association of serum lactate dehydrogenase level with selected opportunistic infections and HIV progression. Int J Infect Dis 2002; 6:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/50\">",
"      Horner RD, Bennett CL, Rodriguez D, et al. Relationship between procedures and health insurance for critically ill patients with Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 1995; 152:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/51\">",
"      Glenny RW, Pierson DJ. Cost reduction in diagnosing Pneumocystis carinii pneumonia. Sputum induction versus bronchoalveolar lavage as the initial diagnostic procedure. Am Rev Respir Dis 1992; 145:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/52\">",
"      Zaman MK, Wooten OJ, Suprahmanya B, et al. Rapid noninvasive diagnosis of Pneumocystis carinii from induced liquefied sputum. Ann Intern Med 1988; 109:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/53\">",
"      Cruciani M, Marcati P, Malena M, et al. Meta-analysis of diagnostic procedures for Pneumocystis carinii pneumonia in HIV-1-infected patients. Eur Respir J 2002; 20:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/54\">",
"      Levine SJ, Masur H, Gill VJ, et al. Effect of aerosolized pentamidine prophylaxis on the diagnosis of Pneumocystis carinii pneumonia by induced sputum examination in patients infected with the human immunodeficiency virus. Am Rev Respir Dis 1991; 144:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/55\">",
"      O'Donnell WJ, Pieciak W, Chertow GM, et al. Clearance of Pneumocystis carinii cysts in acute P carinii pneumonia: assessment by serial sputum induction. Chest 1998; 114:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/56\">",
"      Willocks L, Burns S, Cossar R, Brettle R. Diagnosis of Pneumocystis carinii pneumonia in a population of HIV-positive drug users, with particular reference to sputum induction and fluorescent antibody techniques. J Infect 1993; 26:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/57\">",
"      Levine SJ, Kennedy D, Shelhamer JH, et al. Diagnosis of Pneumocystis carinii pneumonia by multiple lobe, site-directed bronchoalveolar lavage with immunofluorescent monoclonal antibody staining in human immunodeficiency virus-infected patients receiving aerosolized pentamidine chemoprophylaxis. Am Rev Respir Dis 1992; 146:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/58\">",
"      Bustamante EA, Levy H. Sputum induction compared with bronchoalveolar lavage by Ballard catheter to diagnose Pneumocystis carinii pneumonia. Chest 1994; 105:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/59\">",
"      Sax PE, Komarow L, Finkelman MA, et al. Blood (1-&gt;3)-beta-D-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumonia. Clin Infect Dis 2011; 53:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/60\">",
"      Alvarez F, Bandi V, Stager C, Guntupalli KK. Detection of Pneumocystis carinii in tracheal aspirates of intubated patients using calcofluor-white (Fungi-Fluor) and immunofluorescence antibody (Genetic Systems) stains. Crit Care Med 1997; 25:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/61\">",
"      Benfield TL, Prent&oslash; P, Junge J, et al. Alveolar damage in AIDS-related Pneumocystis carinii pneumonia. Chest 1997; 111:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/62\">",
"      Metersky ML, Colt HG, Olson LK, Shanks TG. AIDS-related spontaneous pneumothorax. Risk factors and treatment. Chest 1995; 108:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/63\">",
"      Fischer S, Gill VJ, Kovacs J, et al. The use of oral washes to diagnose Pneumocystis carinii pneumonia: a blinded prospective study using a polymerase chain reaction-based detection system. J Infect Dis 2001; 184:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/64\">",
"      Larsen HH, Masur H, Kovacs JA, et al. Development and evaluation of a quantitative, touch-down, real-time PCR assay for diagnosing Pneumocystis carinii pneumonia. J Clin Microbiol 2002; 40:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/65\">",
"      Zingale A, Carrera P, Lazzarin A, Scarpellini P. Detection of Pneumocystis carinii and characterization of mutations associated with sulfa resistance in bronchoalveolar lavage samples from human immunodeficiency virus-infected subjects. J Clin Microbiol 2003; 41:2709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/66\">",
"      Schluger N, Godwin T, Sepkowitz K, et al. Application of DNA amplification to pneumocystosis: presence of serum Pneumocystis carinii DNA during human and experimentally induced Pneumocystis carinii pneumonia. J Exp Med 1992; 176:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/67\">",
"      Lipschik GY, Gill VJ, Lundgren JD, et al. Improved diagnosis of Pneumocystis carinii infection by polymerase chain reaction on induced sputum and blood. Lancet 1992; 340:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/68\">",
"      Olsson M, Elvin K, L&ouml;fdahl S, Linder E. Detection of Pneumocystis carinii DNA in sputum and bronchoalveolar lavage samples by polymerase chain reaction. J Clin Microbiol 1993; 31:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/69\">",
"      Torres J, Goldman M, Wheat LJ, et al. Diagnosis of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients with polymerase chain reaction: a blinded comparison to standard methods. Clin Infect Dis 2000; 30:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7577/abstract/70\">",
"      Oz HS, Hughes WT. Search for Pneumocystis carinii DNA in upper and lower respiratory tract of humans. Diagn Microbiol Infect Dis 2000; 37:161.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3704 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-A392849A5D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_25_7577=[""].join("\n");
var outline_f7_25_7577=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1429656\">",
"      TAXONOMY AND TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Morphology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Antigenic variability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Colonization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Clinical symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      RADIOGRAPHIC MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      OTHER LABORATORY STUDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      USE OF EMPIRIC THERAPY FOR PCP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DEFINITIVE DIAGNOSIS OF PCP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Sputum induction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26350715\">",
"      Serum 1-3-beta-D-glucan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Other procedures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26350701\">",
"      - Endotracheal aspirates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26350708\">",
"      - Transthoracic needle biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Diagnosis of PCP in patients on prophylactic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3704\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3704|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/0/24580\" title=\"diagnostic image 1\">",
"      PCP in AIDS PA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/24/7554?source=related_link\">",
"      Patient information: Pneumocystis pneumonia (PCP) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20678?source=related_link\">",
"      Pneumothorax in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2889?source=related_link\">",
"      Prophylaxis against Pneumocystis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27593?source=related_link\">",
"      Treatment of Pneumocystis infection in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_25_7578="Glycemic control and vascular complications in type 2 diabetes mellitus";
var content_f7_25_7578=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Glycemic control and vascular complications in type 2 diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/25/7578/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/25/7578/contributors\">",
"     David K McCulloch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/25/7578/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/25/7578/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/25/7578/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/25/7578/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/25/7578/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of tight glycemic control for protection against microvascular and cardiovascular disease in diabetes was established in the",
"    <span class=\"nowrap\">",
"     DCCT/EDIC",
"    </span>",
"    study for type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Although the role of glycemic control on microvascular disease in type 2 diabetes was documented in the United Kingdom Prospective Diabetes Study (UKPDS), its role in reducing cardiovascular risk has not been established as clearly for type 2 diabetes.",
"   </p>",
"   <p>",
"    The effects of glycemic control on microvascular and macrovascular complications in type 2 diabetes will be reviewed here. Glycemic control and vascular complications in type 1 diabetes, the mechanism by which hyperglycemia might cause these complications, and an overview of the treatment of diabetes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=see_link\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=see_link\">",
"     \"Overview of medical care in adults with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HYPERGLYCEMIA AND MICROVASCULAR DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperglycemia is an important risk factor for the development of microvascular disease in patients with type 2 diabetes, as it is in patients with type 1 diabetes. This has been shown in several observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In addition, improving glycemic control improves microvascular outcomes, as illustrated by the findings of a meta-analysis of randomized trials (25,760 participants) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/5\">",
"     5",
"    </a>",
"    ]. There was a reduction in the risk of microvascular complications (a composite outcome including progression of nephropathy, manifestation and progression of retinopathy, and retinal photocoagulation) in the intensive compared with standard glycemic control group (RR 0.89, 95% CI 0.83-0.95). There were significant reductions in risk for each of the individual components.",
"   </p>",
"   <p>",
"    In a subsequent meta-analysis of 7 trials (28,065 adults) evaluating the benefits of intensive versus conventional glycemic control specifically on renal outcomes, there was a statistically significant reduction in the risk of microalbuminuria and macroalbuminuria in patients randomly assigned to intensive glycemic control (risk ratios of 0.86 and 0.74, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/6\">",
"     6",
"    </a>",
"    ]. The reduction in risk of end stage renal disease did not reach statistical significance (RR 0.69, 95% CI 0.46-1.05). There was no reduction in the risk of doubling of the serum creatinine level or death from renal disease (RRs 1.06 and 0.99, respectively). Of note, the majority of the trials in the meta-analysis were not of long enough duration to show a beneficial effect of glycemic control on end stage renal disease, which typically manifests after 10 to 20 years of diabetes duration [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/7\">",
"     7",
"    </a>",
"    ]. In the trials included in the meta-analysis, the absolute rates of severe renal outcomes were low in both the intensive and conventional therapy groups, reducing the ability of the analysis to demonstrate a benefit, if one exists. In the one trial with longer-term follow-up (UKPDS cohort followed for 22 years), there was a beneficial effect of intensive therapy on the development of more advanced clinical outcomes, including renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Post-trial monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The major trials are described below:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     United Kingdom Prospective Diabetes Study",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UKPDS was designed to compare the efficacy of different treatment regimens (diet, sulfonylurea,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , and insulin) on glycemic control and the complications of diabetes in about 4000 newly diagnosed patients with type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The target fasting blood glucose concentration was 108",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    or less. Patients in the intensive-therapy group received a sulfonylurea (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/0/6151?source=see_link\">",
"     chlorpropamide",
"    </a>",
"    , glibenclamide, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/28/40391?source=see_link\">",
"     glipizide",
"    </a>",
"    ) or insulin; metformin was added to the sulfonylurea if the fasting blood glucose concentration was greater than 270",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (15",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    with the latter alone, and insulin was initiated if the combination of oral agents remained ineffective. The conventional-therapy group was treated with diet alone; drugs were added if there were hyperglycemic symptoms or if the fasting blood glucose concentration was greater than 270",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (15",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Over 10 years, the average A1C value was 7.0 percent in the intensive-therapy group compared with 7.9 percent in the conventional-therapy group (an 11 percent reduction) (",
"      <a class=\"graphic graphic_figure graphicRef81706 \" href=\"UTD.htm?17/5/17502\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The risk for any diabetes-related endpoint (see abstract for definition of endpoints [",
"      <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/9\">",
"       9",
"      </a>",
"      ]) was 12 percent lower in the intensive-therapy group (p = 0.029) and 10 percent lower for any diabetes-related death (p = 0.34) (",
"      <a class=\"graphic graphic_figure graphicRef69142 \" href=\"UTD.htm?15/55/16254\">",
"       figure 2",
"      </a>",
"      ). It was estimated that 19.6 patients would have to be treated to prevent any single endpoint in one patient in 10 years.",
"     </li>",
"     <li>",
"      Most of the risk reduction in the intensive therapy group was due to a 25 percent risk reduction in microvascular disease (p = 0.001) (",
"      <a class=\"graphic graphic_figure graphicRef52273 \" href=\"UTD.htm?36/32/37389\">",
"       figure 3",
"      </a>",
"      ); there was a borderline statistically significant (p = 0.052) reduction in macrovascular disease. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'UKPDS'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The benefits of intensive therapy appeared to be independent of the type of treatment administered.",
"     </li>",
"     <li>",
"      Patients in the intensive therapy group had more hypoglycemic episodes and weight gain; weight gain was greater in those receiving insulin (4.0 kg) than in those receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/0/6151?source=see_link\">",
"       chlorpropamide",
"      </a>",
"      (2.6 kg) or glibenclamide (1.7 kg).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The reduction in microvascular complications in patients receiving intensive therapy was of a smaller magnitude than in patients with type 1 diabetes in the DCCT [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/1\">",
"     1",
"    </a>",
"    ]. In the DCCT, for example, the incidence of new retinopathy was 12 percent with intensive therapy versus 54 percent with conventional therapy. One possible explanation for this difference is that the difference in A1C values was smaller between the intensive and conventional therapy groups in the UKPDS (7.0 versus 7.9 percent) compared with the DCCT (7.2 versus 9.1 percent).",
"   </p>",
"   <p>",
"    A subset of 753 overweight patients (mean BMI 31",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    was included in a separate treatment arm in which intensive blood glucose control with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    was compared with conventional therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/11\">",
"     11",
"    </a>",
"    ]. The comparison of metformin and dietary policy (control) in the overweight group showed a similar magnitude reduction in microvascular outcomes (specifically retinal outcomes or renal disease) as in the sulfonylurea and insulin-treated groups, but it did not achieve a statistical significance, perhaps due to poor power.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Post-trial monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following completion of the UKPDS in 1997, all surviving patients (n = 3277) entered a post-trial monitoring program [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/8\">",
"     8",
"    </a>",
"    ]. Subjects received care from community or hospital-based clinicians with no attempt to maintain previously randomized therapy but with a universal goal of achieving lower levels of glucose and blood pressure. They were evaluated by annual UKPDS clinic visits for five years and by questionnaire in years 6 through 10.",
"   </p>",
"   <p>",
"    Although mean A1C level (7.9 and 8.5 percent, respectively) was better in the intensive versus conventional therapy group at the beginning of the post-trial monitoring period, baseline differences were lost by one year. After five years of post-trial observation, there were no significant differences in A1C (approximately 7.8 percent), body weight, lipid levels, or blood pressure in patients previously assigned to intensive or conventional groups.",
"   </p>",
"   <p>",
"    Reductions in the relative risk of diabetes-related endpoints and microvascular disease that had been noted in the intensively treated patients (sulfonylurea-insulin) during the intervention trial were maintained in the postinterventional period despite similar glycemic control. During the entire follow-up period (a median of 17 years), the risk of microvascular complications in the group formerly assigned to intensive treatment with sulfonylurea-insulin remained lower than those formerly assigned to conventional treatment (relative risk [RR] 0.76, 95% CI 0.64-0.89).",
"   </p>",
"   <p>",
"    The long-term follow-up of the overweight subcohort assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    or dietary intervention during the active trial continued to show no statistically significant difference in microvascular outcomes, again perhaps related to limited power [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Kumamoto study",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a trial of 110 patients with type 2 diabetes from Japan, intensive therapy was also beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/12\">",
"     12",
"    </a>",
"    ]. A group of 55 patients with urinary albumin excretion less than 30",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and no evidence of retinopathy (the primary prevention cohort) was randomly assigned to receive multiple doses of insulin or less intensive insulin treatment (treatment regimens patterned after the DCCT). The other 55 patients with evidence of simple retinopathy and urinary albumin excretion above 30",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (the secondary intervention cohort) were randomly assigned to the same treatment regimens. The goal of therapy in the multiple-dose insulin groups was to reduce the A1C value below 7.0 percent. The following benefits were noted in the multi-dose insulin group, which achieved a mean A1C of 7.1 percent compared with 9.4 percent in the control group:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A lower incidence of the development or progression of retinopathy after six years (7.7 percent versus 32.0 percent in the primary prevention cohort and 19.2 percent versus 44.0 percent in the secondary intervention cohort).",
"     </li>",
"     <li>",
"      A lower incidence of the development or progression of nephropathy after six years (7.7 percent versus 28.0 percent in the primary prevention cohort and 11.5 percent versus 32.0 percent in the secondary intervention cohort).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most of these Japanese patients were young adults and had a body mass index in the low-normal range. The UKPDS was a much larger study that included older, heavier patients, more consistent with the characteristics of type 2 diabetes in western populations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     ADVANCE trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the ADVANCE trial (see",
"    <a class=\"local\" href=\"#H14\">",
"     'ADVANCE'",
"    </a>",
"    below), 5571 type 2 diabetes patients receiving intensive therapy to lower A1C (mean A1C 6.5 percent) had a reduction in the incidence of nephropathy, defined as development of macroalbuminuria, doubling of the serum creatinine to at least 2.26",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (200",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    the need for renal-replacement therapy, or death due to renal disease (4.1 versus 5.2 percent, hazard ratio [HR] 0.79, 95% CI 0.66-0.93) compared with 5569 patients receiving standard therapy (A1C 7.3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/13\">",
"     13",
"    </a>",
"    ]. There was no significant effect of glycemic control on the incidence of retinopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Veteran's Affairs Diabetes Trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the Veteran's Affairs Diabetes Trial (VADT) (see",
"    <a class=\"local\" href=\"#H12\">",
"     'VACSDM/VADT'",
"    </a>",
"    below), 892 veterans with long-standing type 2 diabetes receiving intensive therapy (A1C 6.9 percent) did not have a reduction in retinopathy or major nephropathy outcomes, which were predefined secondary endpoints, compared with 899 veterans receiving standard therapy (A1C 8.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/14\">",
"     14",
"    </a>",
"    ]. The limited number of subjects and follow-up time (median of 5.6 years) may explain, in part, the discrepant findings from those of the UKPDS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11243121\">",
"    <span class=\"h2\">",
"     ACCORD trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the ACCORD trial (see",
"    <a class=\"local\" href=\"#H13\">",
"     'ACCORD'",
"    </a>",
"    below), 10,250 patients with long-standing type 2 diabetes were randomly assigned to intensive or standard glycemic control. After a median follow-up of 3.7 years, intensive therapy was stopped due to a higher number of total and cardiovascular deaths in subjects assigned to intensive therapy (median A1C 6.4 percent) compared with the standard treatment group (median A1C 7.5 percent). Patients in the intensive therapy arm were transitioned to standard therapy, and all patients were followed for microvascular outcomes, predefined secondary endpoints, until completion of the study (five years) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/15\">",
"     15",
"    </a>",
"    ]. The median A1C in the intensive group remained lower than in the standard therapy group (7.2 versus 7.6 percent at study end). There were two composite microvascular outcomes. The first was dialysis or renal transplantation, high serum creatinine (&gt;3.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [291.72",
"    <span class=\"nowrap\">",
"     micromol/L]),",
"    </span>",
"    or retinal photocoagulation or vitrectomy to treat diabetic retinopathy (designed to be similar to the UKPDS microvascular aggregate outcome), and the second was peripheral neuropathy plus the first composite outcome. The difference in the number of patients experiencing either composite outcome at study transition or at study end was not significant (HR 0.95 for both composite outcomes at study end, with CIs 0.85-1.07 and 0.89-1.01 for the first and second outcomes, respectively). There was a significant decrease in the incidence of microvascular renal outcomes in the intensive therapy group at study transition and study end (HR 0.85, 95% CI 0.77-0.94 for microalbuminuria at study end).",
"   </p>",
"   <p>",
"    In a substudy of the ACCORD trial, the ACCORD Eye study, 2856 participants were evaluated for the effects of intensive (median A1C 6.4 percent) or standard (median A1C 7.5 percent) glycemia therapy on the progression of diabetic retinopathy measured by fundus photography [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/16\">",
"     16",
"    </a>",
"    ]. Progression of diabetic retinopathy was defined by three or more steps on the Early Treatment Diabetic Retinopathy Study (ETDRS) Severity Scale or the development of proliferative retinopathy requiring photocoagulation or vitrectomy. At four years, there was a reduction in the proportion of patients with progression of retinopathy in the intensive therapy group (7.3 versus 10.4 percent, adjusted odds ratio 0.67, 95% CI 0.51-0.87). There was no difference in the rate of moderate vision loss (16.3 versus 16.7 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Microvascular summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of the UKPDS, Kumamoto, ADVANCE, and ACCORD trials are consistent with those of the DCCT for patients with type 1 diabetes, taking into account the relative differences in A1C achieved between treatment groups and the differences in study duration (or exposure): intensive therapy improves the outcome of microvascular disease (primarily retinopathy, nephropathy). In the UKPDS, there was no evidence of a threshold effect for A1C; a 1 percent fall in A1C was associated with a 35 percent reduction in microvascular endpoints. In addition, the results of the post-trial monitoring phase of the UKPDS show that a sustained period of glycemic control in newly diagnosed patients with type 2 diabetes has lasting benefit in reducing microvascular disease.",
"   </p>",
"   <p>",
"    The lack of benefit of intensive control in VADT may be secondary to the duration of diabetes in subjects participating in VADT (mean 11.5 years versus newly diagnosed in UKPDS) and the time required to show benefit (delayed benefit may require longer follow-up). In addition, aggressive treatment of hypertension and hyperlipidemia in all VADT participants may have contributed to the inability to show a microvascular benefit of intensive glucose control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MACROVASCULAR DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic analyses (observational studies or secondary analyses of trials) suggest a correlation between higher rates of cardiovascular disease (CVD) and chronic hyperglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/17-22\">",
"     17-22",
"    </a>",
"    ]. As an example, in a meta-analysis of 13 prospective cohort studies (10 in type 2 diabetes, including the UKPDS), for every one percentage point increase in glycated hemoglobin, the relative risk for any cardiovascular event was 1.18 (95% CI 1.10-1.26) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=see_link\">",
"     \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Intensive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the association described above suggests that improvements in A1C values may reduce cardiovascular outcomes, to date, most randomized clinical trials have not demonstrated a beneficial effect of intensive therapy on macrovascular outcomes in type 2 diabetes. The VADT, ACCORD, and ADVANCE trials described below were designed to study the effects of intensive versus conventional therapy on cardiovascular outcomes in subjects with long-standing diabetes (duration 8 to 12 years). None show a benefit of intensive control, and results from ACCORD showed a significant increase in total (HR 1.22) and CVD (HR 1.35) mortality with intensive therapy.",
"   </p>",
"   <p>",
"    In contrast to these trials, the UKPDS was designed to investigate the role of glycemic control on the complications of diabetes in newly diagnosed patients. The UKPDS postinterventional study showed a benefit of initial intensive glycemic control (to achieve an A1C of 7.0 percent) on CVD in these individuals. However, the average level of diabetes control was generally higher in the UKPDS, use of non-glycemic interventions recognized to reduce CVD was less frequent, and follow-up was longer in the UKPDS than in the other trials.",
"   </p>",
"   <p>",
"    The PROactive trial was specifically designed to evaluate the effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    (not intensive glycemic control) on cardiovascular events and mortality in 5238 patients with type 2 diabetes at high risk for macrovascular complications (prior MI, stroke, CABG, acute coronary syndrome or symptomatic peripheral artery disease). The study was stopped prematurely because of a significant decrease in the \"main\" secondary composite endpoint of all-cause mortality, MI (excluding silent MI), or stroke (defined after the trial was underway, and one of eight secondary outcomes) in the pioglitazone group. The study is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=see_link&amp;anchor=H14#H14\">",
"     \"Thiazolidinediones in the treatment of diabetes mellitus\", section on 'Pioglitazone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In meta-analyses including these trials (UKPDS, VADT, ACCORD, ADVANCE, with or without PROactive), there was a reduction in the risk for coronary heart disease (eg, RR 0.89, 95% CI 0.81-0.96) and non-fatal MI (RR 0.84, 95% CI 0.75-0.94) with intensive glucose-lowering versus standard treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. However, intensive treatment did not significantly affect stroke, all-cause, or cardiovascular mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/5,23-26\">",
"     5,23-26",
"    </a>",
"    ]. These findings differ from the results of the individual trials (VADT, ACCORD, ADVANCE) and are likely related to differences in study design, which are discussed in detail below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     UKPDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UKPDS was designed to investigate the role of glycemic control on the complications of diabetes in newly diagnosed patients. There was no statistically significant difference in macrovascular disease in the intensive and conventional therapy groups (mean A1C values of 7.0 and 7.9 percent, respectively) in the primary analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'United Kingdom Prospective Diabetes Study'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A subset of 753 overweight patients (mean BMI 31",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    was included in a separate treatment arm in which intensive blood glucose control with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    was compared with conventional therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/11\">",
"     11",
"    </a>",
"    ]. A secondary analysis compared the 342 patients allocated to metformin with 951 patients receiving intensive therapy with a sulfonylurea or insulin. Compared with conventional therapy, treatment with metformin resulted in significant risk reductions of 32 percent for any diabetes-related endpoint (endpoints included both macrovascular and microvascular complications), 42 percent for diabetes-related death, and 36 percent for all-cause mortality. Metformin also had a greater effect upon any diabetes-related endpoint and all-cause mortality than intensive therapy with a sulfonylurea or insulin (p = 0.003) (",
"    <a class=\"graphic graphic_figure graphicRef55216 graphicRef67969 \" href=\"UTD.htm?19/5/19536\">",
"     figure 4A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    During the post-interventional observation period, significant reductions in the risk of macrovascular complications emerged in the sulfonylurea-insulin group and were maintained in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    group [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/8\">",
"     8",
"    </a>",
"    ]. During the entire follow-up period (approximately 17 years), there were fewer overall deaths (RRs 0.87, 95% CI 0.79-0.96 and 0.73, 95% CI 0.59-0.89), diabetes-related deaths (RRs 0.83, 95% CI 0.73-0.96 and 0.70, 95% CI 0.53-0.92), and myocardial infarction (RRs 0.85, 95% CI 0.74-0.97 and 0.67, 95% CI 0.51-0.89) in subjects who were initially assigned to intensive treatment with sulfonylurea, insulin or metformin, respectively, compared with those assigned to conventional therapy. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Post-trial monitoring'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    These results indicate that a sustained period of glycemic control (10 years) in newly diagnosed patients with type 2 diabetes has a long-term benefit in reducing cardiovascular morbidity and mortality. The results are supported by similar findings from the postinterventional follow-up of subjects enrolled in the Steno-2 trial. This trial is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of medical care in adults with diabetes mellitus\", section on 'Multifactorial risk factor reduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     VACSDM/VADT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a feasibility trial from the Veterans Affairs Cooperative Study of Diabetes Mellitus (VACSDM), intensive insulin therapy in 153 men with type 2 diabetes (mean duration 7.8 years) was associated with an increase in the frequency of hypoglycemia and a non-significant increase in cardiovascular events [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/27\">",
"     27",
"    </a>",
"    ]. The main predictor of cardiovascular events during the study, as expected, was a history of previous cardiovascular disease. However, even after correcting for baseline cardiac abnormalities, a lower A1C value was significantly correlated with an increase in new cardiovascular events.",
"   </p>",
"   <p>",
"    In a longer-term prospective trial, the Veteran's Affairs Diabetes Trial of Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT), 1791 veterans (mean age 60 years) with type 2 diabetes (mean duration 11.5 years) were randomly assigned to intensive therapy (aiming to achieve a normal A1C) or to conventional therapy (A1C separation of greater than 1.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/28\">",
"     28",
"    </a>",
"    ]. A variety of agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8823?source=see_link\">",
"     glimepiride",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    , insulin) were used to achieve goals.",
"   </p>",
"   <p>",
"    After 5.6 years (median), there was no difference in the first occurrence of any cardiovascular event (composite of stroke, death from cardiovascular causes, CHF, surgery for vascular disease, inoperable coronary disease, amputation for ischemic gangrene) between the intensive (achieved A1C 6.9 percent) and standard (A1C 8.4 percent) groups (HR in the intensive group 0.88, 95% CI 0.74-1.05) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, there was no difference between groups in time to death from cardiovascular causes (HR 1.32, 95% CI 0.81-2.14) or death from any cause (HR 1.07, 95% CI 0.81-1.42). Hypoglycemia occurred more frequently in the intensive group (8.5 versus 3.1 percent), including episodes with impaired or complete loss of consciousness (12 versus 4 per 100 patient-years).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     ACCORD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, a multicenter study of type 2 diabetes, was designed primarily to examine the effects of glycemic control, lower than had previously been achieved, on cardiovascular disease in subjects with long-standing diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/29\">",
"     29",
"    </a>",
"    ]. The study cohort of 10,250 adults (mean age 62 years) with a median diabetes duration of 10 years and at high risk for cardiovascular disease (diagnosed with CVD or two risk factors in addition to diabetes) was randomly assigned to an intensive treatment group with the aim of achieving A1C of less than 6 percent or a standard treatment group with a A1C goal of 7.0 to 7.9 percent. The diabetes treatment strategies took advantage of an algorithmic approach using numerous diabetes medications.",
"   </p>",
"   <p>",
"    In addition, in this factorial study, approximately one-half of the population was assigned to a blood pressure study (intensive therapy aiming for systolic blood pressure &lt;120 mmHg and conventional aiming for systolic BP &lt;140 mmHg) and one-half to a lipid study in which all subjects were treated with a statin, but one-half randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/23/17784?source=see_link\">",
"     fenofibrate",
"    </a>",
"    and one-half to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\", section on 'ACCORD BP trial'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link&amp;anchor=H31#H31\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'ACCORD Lipid trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In 2008, the intensive blood sugar lowering arm of the study was halted based upon a recommendation of the external Data Safety Monitoring Board due to a higher number of total and cardiovascular deaths (257 versus 203) in subjects assigned to intensive therapy (HR 1.22 95% CI 1.01-1.46) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Over an average of 3.5 years, there was an excess of three deaths per 1000 subjects per year in the intensive group. However, the rate of death in both treatment groups was lower than that reported in other studies of type 2 diabetes. The primary outcome (a composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) occurred in 352 and 371 patients in the intensive and standard therapy groups, respectively (HR 0.90, 95% CI 0.78-1.04).",
"   </p>",
"   <p>",
"    Extensive analyses did not identify a specific cause for the excess mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/31,33\">",
"     31,33",
"    </a>",
"    ]. Subjects in the intensive group rapidly achieved target A1C values (median A1C decreased from 8.1 to 6.7 percent in four months and was 6.4 percent after 3.5 years) and experienced a greater number of severe hypoglycemic events (annualized rate of 3.1 versus 1.0 percent) and more weight gain (mean 3.5 versus 0.4 kg at three years) than the standard group (median A1C 7.5 percent). However, more frequent hypoglycemia did not apparently account for the difference in the death rate, nor did a specific medication or combination of medicines.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     Rosiglitazone",
"    </a>",
"    , in particular, was not linked to the difference in mortality. The design of ACCORD limits the ability to determine whether the differences in glycemia between the treatment groups or the different profile of medications utilized to achieve the glycemic levels was responsible for the excess mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21498942\">",
"    <span class=\"h4\">",
"     Post-termination monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;After a mean of 3.7 years of intensive therapy, patients in the intensive therapy arm were transitioned to standard therapy and all patients were followed for cardiovascular outcomes until completion of the study (five years) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/34\">",
"     34",
"    </a>",
"    ]. The median A1C in the intensive group remained lower than in the standard therapy group (7.2 versus 7.6 percent at study end). The findings at five years were similar to those reported when the study was terminated [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/32\">",
"     32",
"    </a>",
"    ]. The number of total and cardiovascular deaths (578 versus 471) was higher in subjects assigned to intensive therapy (HR for death from any cause 1.19, 95% CI 1.03-1.38) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/34\">",
"     34",
"    </a>",
"    ]. There were fewer nonfatal myocardial infarctions in the intensively treated patients (287 versus 344, HR 0.82, 95% CI 0.70-0.96). The primary outcome (a composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) occurred in 503 and 543 patients in the intensive and standard therapy groups, respectively (HR 0.91, 95% CI 0.81-1.03). The reason for the higher mortality in the intensively treated patients remains unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     ADVANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ADVANCE trial was designed to evaluate the effects of intensive glycemic therapy (based on treatment with the sulfonylurea",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/42/34470?source=see_link\">",
"     gliclazide",
"    </a>",
"    ) and blood pressure control on cardiovascular disease in patients with long-standing type 2 diabetes at high risk for vascular disease. The results of the blood pressure lowering arm are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\", section on 'ADVANCE trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the intensive glucose lowering arm, 11,140 patients (mean age 66 years, mean duration of diabetes eight years) were randomly assigned to either standard therapy or modified-release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/42/34470?source=see_link\">",
"     gliclazide",
"    </a>",
"    (30 to 120 mg) plus other drugs as required to achieve an A1C of &lt;6.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/13\">",
"     13",
"    </a>",
"    ]. After a median of five years of follow-up, the intensive and standard groups achieved mean A1C values of 6.5 and 7.3 percent, respectively, with the A1C in the intensive group on average 0.67 percent lower.",
"   </p>",
"   <p>",
"    Unlike the findings described above in the ACCORD trial, ADVANCE did not show an increased risk of death among patients receiving intensive therapy compared with standard therapy (HR for death from cardiovascular causes with intensive control 0.88, 95% CI 0.74-1.04 and HR for death from any cause 0.93, 95% CI 0.83-1.06). As in ACCORD and VADT, there was no benefit of intensive therapy on the primary composite endpoint of cardiovascular death, nonfatal MI, or nonfatal stroke (HR 0.94, 95% CI 0.84-1.06).",
"   </p>",
"   <p>",
"    Severe hypoglycemia occurred in more patients in the intensively treated arm (2.7 versus 1.5 percent). Among patients who had severe hypoglycemia compared with those who did not, the risk of a major macrovascular event, major microvascular event, and death (total and cardiovascular) was significantly increased (HRs 2.07 to 3.78) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/35\">",
"     35",
"    </a>",
"    ]. The association between severe hypoglycemia and risk of a microvascular event, macrovascular event, or death was similar for patients assigned to standard and intensive glycemic control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Macrovascular summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the difference in mortality findings between ACCORD and",
"    <span class=\"nowrap\">",
"     ADVANCE/VADT",
"    </span>",
"    and the difference in cardiovascular outcomes between",
"    <span class=\"nowrap\">",
"     ACCORD/ADVANCE/VADT",
"    </span>",
"    and the meta-analyses are unexplained, there are some differences among the trials that could account for the discrepancies, including choice of pharmacologic therapy, baseline glycemic control, and frequency of hypoglycemia. As an example, in the intensively treated arm of the ACCORD trial, more than 90 percent of subjects were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    and 77 percent were taking insulin, whereas in the ADVANCE trial, the intensive treatment cohort subjects were all assigned to a sulfonylurea, and thiazolidinediones and insulin were used in only 16 and 40 percent, respectively. In VADT, insulin use (90 and 74 percent, respectively) and rosiglitazone use (72 and 62 percent, respectively) were common in both the intensive and standard groups.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    use was high among all patients in both ACCORD and ADVANCE (94 and 73 percent, respectively, in intensively treated patients).",
"   </p>",
"   <p>",
"    Median baseline A1C was higher in VADT than in ACCORD and ADVANCE subjects (9.4, 8.1, and 7.2 percent, respectively). A1C values were rapidly lowered during the first four months of the ACCORD trial, and there was a greater difference between the intensive and standard groups with regards to hypoglycemic events and weight gain.",
"   </p>",
"   <p>",
"    Despite these differences, all three trials consistently show that over the time period studied (3.5 to 6 years), near-normal glycemic control (A1C 6.4 to 6.9 percent) does not reduce cardiovascular events in patients with longstanding diabetes. However, in patients with newly diagnosed type 2 diabetes, a goal A1C of &le;7.0 percent is reasonable and supported by the findings of the UKPDS follow-up study. Whether a benefit of stricter control (A1C near-normal) in newly diagnosed patients will eventually be demonstrated is uncertain.",
"   </p>",
"   <p>",
"    The most effective approach for prevention of macrovascular complications appears to be multifactorial risk factor reduction (glycemic control, stopping smoking, aggressive blood pressure control, treatment of dyslipidemia, and for secondary prevention, daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ). The benefits of this approach are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of medical care in adults with diabetes mellitus\", section on 'Multifactorial risk factor reduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Metformin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the UKPDS, treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    resulted in significant risk reductions for any diabetes-related endpoint (endpoints included both macrovascular and microvascular complications). A subsequent smaller trial similarly showed a reduction in macrovascular endpoints with metformin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/36\">",
"     36",
"    </a>",
"    ]. In this trial, 390 patients treated with insulin were randomly assigned to metformin versus placebo. After four years, mean A1C (7.5 versus 7.9 percent) and body weight (85 versus 90 kg) were significantly lower in the metformin group. In addition, there was a decrease in the risk of the secondary macrovascular endpoint, which was a composite of 13 vascular events, including myocardial infarction, heart failure, stroke, amputation, and sudden death (event rates 15 versus 18 percent, adjusted HR 0.60, 95% CI 0.4-0.9).",
"   </p>",
"   <p>",
"    An unexpected finding in a UKPDS substudy was that the early addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    in patients already receiving a sulfonylurea was associated with a 96 percent increase in the risk of diabetes-related death compared with continuation of the sulfonylurea alone (p = 0.04) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/11\">",
"     11",
"    </a>",
"    ]. It is not clear how to interpret these data, as the analyses are secondary and not internally consistent. On the one hand, metformin appears to be beneficial as initial therapy in overweight patients with type 2 diabetes. However, the evidence of an adverse effect with the early addition of metformin to sulfonylurea therapy is troubling.",
"   </p>",
"   <p>",
"    The results of larger trials are reassuring, although they were not specifically designed to address this issue [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/13,28,32\">",
"     13,28,32",
"    </a>",
"    ]. In ADVANCE, the majority of subjects were taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , regardless of treatment assignment (74 and 67 percent of those assigned to intensive versus conventional therapy, respectively). However, a sulfonylurea (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/42/34470?source=see_link\">",
"     gliclazide",
"    </a>",
"    ) was used, by design, by a significantly greater proportion of subjects in the intensive group (90 versus 16 percent). As discussed above, there was no difference in mortality between intensive and conventionally treated subjects in the ADVANCE trial.",
"   </p>",
"   <p>",
"    In the ACCORD trial, the majority of subjects in both groups were taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    (94 and 87 percent of those assigned to intensive versus conventional therapy, respectively) and many in both groups (78 and 67 percent, respectively) were taking a sulfonylurea. Although the study was halted due to a higher number of total and cardiovascular deaths in subjects assigned to intensive therapy, a specific medication or combination of medicines did not apparently account for the difference. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'ACCORD'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Thiazolidinediones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thiazolidinediones improve a number of cardiovascular risk factors and surrogate cardiovascular endpoints, including dyslipidemia, markers of inflammation, vascular smooth muscle proliferation, vascular reactivity, endothelial function, and carotid intima media thickness [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. However, data demonstrating their ability to decrease cardiovascular events are unimpressive and concerns about side effects (weight gain, fluid retention, heart failure, MI, and fractures) persist. Thiazolidinediones are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=see_link&amp;anchor=H8#H8\">",
"     \"Thiazolidinediones in the treatment of diabetes mellitus\", section on 'Cardiovascular Effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28569?source=see_link&amp;anchor=H9#H9\">",
"     \"Heart failure in diabetes mellitus\", section on 'Thiazolidinediones'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Prediabetes and cardiovascular risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is strong, consistent evidence that the relationship between blood glucose levels and cardiovascular risk extends into the nondiabetic range [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. As an example, in a cohort of 4662 men aged 45 to 79 years followed from 1995 to 1999, both all cause mortality and cardiovascular deaths were significantly higher among those with A1C in the high end of the normal range compared with those whose A1C was &le;5.0 percent (",
"    <a class=\"graphic graphic_figure graphicRef55653 \" href=\"UTD.htm?42/32/43533\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, data from the Atherosclerosis Risk in Communities (ARIC) study show a relationship between A1C level and coronary heart disease in nondiabetic individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/20\">",
"     20",
"    </a>",
"    ]. The relative risk of a cardiovascular event was 1.38 (95% CI 1.22-1.56) for every one percentage point increase in hemoglobin A1C for subjects without diabetes whose A1C was 5.5 percent or greater. The incidence of peripheral vascular disease also correlated with glycemic control [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44197?source=see_link\">",
"     Acarbose",
"    </a>",
"    , an alpha-glucosidase inhibitor, decreases postprandial hyperglycemia and may prevent the development of type 2 diabetes in patients with impaired glucose tolerance. It also appears to reduce the risk of cardiovascular disease and hypertension in this population. However, these findings were hypothesis-generating and require confirmation by further trials. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=see_link\">",
"     \"Prediction and prevention of type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3078?source=see_link&amp;anchor=H5#H5\">",
"     \"Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus\", section on 'Effects on cardiovascular events'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     GLYCEMIC TARGETS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Target A1C levels in patients with type 2 diabetes should be tailored to the individual, balancing the improvement in microvascular complications with the risk of hypoglycemia. Only limited clinical trial data (the long-term follow-up of the UKPDS) have demonstrated a macrovascular benefit with intensive therapy in patients with newly diagnosed type 2 diabetes, and data from the ACCORD trial suggest that lowering A1C to near normal may be unsafe in patients with a long history of diabetes who were at high risk for cardiovascular disease. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'UKPDS'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H13\">",
"     'ACCORD'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Thus, a reasonable goal of therapy might be an A1C value of &le;7.0 percent for most patients (using a",
"    <span class=\"nowrap\">",
"     DCCT/UKPDS",
"    </span>",
"    aligned assay in which the upper limit of normal is 6.0 percent). In order to achieve the A1C goal, a fasting glucose of 70 to 130",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.9 to 7.2",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and a postprandial glucose (90 to 120 minutes after a meal) less than 180",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (10",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    are usually necessary.",
"   </p>",
"   <p>",
"    The results of the ACCORD trial suggest that a target A1C of 7.0 to 7.9 percent (achieving a median of 7.5 percent) may be safer for patients with long-standing type 2 diabetes who are at high risk for cardiovascular disease than a target A1C of 6.0 percent (achieving a median of 6.4 percent). This target is supported by the results of a retrospective cohort study of approximately 48,000 patients with type 2 diabetes, aged 50 years and older, whose treatment had been intensified [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/46\">",
"     46",
"    </a>",
"    ]. After a mean follow-up of approximately 4.5 years, all-cause mortality was highest in those with the lowest (less than 6.7 percent) and highest (9.9 percent) A1C values. An A1C level of 7.5 percent was associated with the lowest all-cause mortality. Similar findings were reported in a population-based cohort study of patients with diabetes and chronic kidney disease (estimated glomerular filtration rate 15 to 59.9",
"    <span class=\"nowrap\">",
"     mL/min/1.73",
"    </span>",
"    m2) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/47\">",
"     47",
"    </a>",
"    ]. There was a U-shaped relationship between A1C and mortality, with risk of mortality increasing with A1C values below 6.5 or above 8 percent.",
"   </p>",
"   <p>",
"    The A1C goal should also be set somewhat higher for older patients and those with a limited life expectancy. The American Geriatrics Society suggests an A1C target of 8 percent for frail older adults and individuals with life expectancy of less than five years. These recommendations are supported by a decision analysis integrating multiple prediction models [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/48\">",
"     48",
"    </a>",
"    ]. In this analysis, comorbid conditions and functional impairment were better predictors of both life expectancy and less benefit from intensive glucose control than age alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/42/682?source=see_link\">",
"     \"Treatment of type 2 diabetes mellitus in the elderly patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2009 ADA and European Association for the Study of Diabetes (EASD) consensus algorithm recommends an A1C of less than 7 percent for most nonpregnant adults, due to the benefits of reducing microvascular complications [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/49\">",
"     49",
"    </a>",
"    ]. However, the guidelines also recommend tailoring A1C goals for individual patients. Less stringent treatment goals may be appropriate for patients with a history of severe hypoglycemia, patients with limited life expectancy, very young children or older adults, and individuals with comorbid conditions.",
"   </p>",
"   <p>",
"    The American Association of Clinical Endocrinologists (AACE) recommendations are similar to those of the ADA, except for the recommendation of a target of A1C less than 6.5 percent for most nonpregnant adults, despite the ACCORD results, if it can be achieved safely [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     COST OF INTENSIVE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cost-effectiveness analysis using the UKPDS cohort found that intensive therapy significantly increased treatment costs [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/51\">",
"     51",
"    </a>",
"    ]. However, these costs were largely offset by a reduction in the cost of complications and an increased time free of complications, similar to DCCT results in type 1 diabetes.",
"   </p>",
"   <p>",
"    A group of investigators developed a Markov type model with Monte Carlo simulation techniques to simulate the natural history of type 2 diabetes using assumptions based upon the best available published epidemiologic, natural history, and intervention studies (prior to publication of results from the ACCORD and ADVANCE trials) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/52\">",
"     52",
"    </a>",
"    ]. They used this model to estimate the cost-effectiveness of treating type 2 diabetes intensively with the goal of normoglycemia and concluded that the incremental cost would be about $16,000 per quality-adjusted-life-year (QALY) gained [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/53\">",
"     53",
"    </a>",
"    ]. However, this favorable estimate was based upon several important assumptions, particularly suboptimal treatment in the standard care group. The cost per QALY would be considerably higher if the standard of care for conventional treatment were improved (eg, avoidance of smoking, use of ACE inhibitors, careful foot care) or if the intensive therapy were less successful or were applied to patients over age 55 years.",
"   </p>",
"   <p>",
"    A second analysis using a Markov decision model found that interventions that reduce A1C values by 2 percent would be most cost-effective if applied to patients who are younger or have higher A1C values [",
"    <a class=\"abstract\" href=\"UTD.htm?7/25/7578/abstract/54\">",
"     54",
"    </a>",
"    ]. As an example, if patients with an A1C value of 12 percent were targeted for the intervention to reduce their A1C value to 10 percent and keep it at that level for life, the number needed to treat to prevent one case of blindness would be 25. By comparison, if this intervention were applied to those whose A1C values were 9 percent (and would be reduced to 7 percent), the number needed to treat would be 181.",
"   </p>",
"   <p>",
"    The authors of this study suggested that 84 percent of the potential benefit from such an intervention could be accomplished by targeting only 17 percent of patients with type 2 diabetes, using the following entry criteria: A1C value above 9 percent for patients who develop diabetes in their 40s, above 10 percent for patients who develop diabetes in their 50s, above 11 percent for those who develop diabetes in their 60s, and above 12 percent for those who develop diabetes in their 70s. While this kind of analysis should not be used to deny any patient the potential benefit of improved glycemic control, it shows where resources might be focused in order to maximize improvements in health outcomes for the population as a whole.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/40/22144?source=see_link\">",
"       \"Patient information: The ABCs of diabetes (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=see_link\">",
"       \"Patient information: Type 2 diabetes (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=see_link\">",
"       \"Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/1/40980?source=see_link\">",
"       \"Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Microvascular complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Improved glycemic control improves the risk of microvascular complications in patients with type 2 diabetes. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Hyperglycemia and Microvascular disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Macrovascular complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;To date, no randomized clinical trial has convincingly demonstrated a beneficial effect of intensive therapy on macrovascular outcomes in individuals with long-standing type 2 diabetes. In contrast, the results of the UKPDS post-trial observation follow-up study suggest that initial intensive control (A1C 7.0 percent) in individuals with newly diagnosed diabetes has long-term benefit in decreasing the risk of myocardial infarction, diabetes-related death, and overall death. In the aggregate, the clinical evidence supports initiating intensive therapy with the goal of lowering A1C levels to &lt;7.0 percent as early as possible in the course of diabetes. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Macrovascular disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Target A1C",
"    </span>",
"    &nbsp;&mdash;&nbsp;A1C goals in patients with type 2 diabetes should be tailored to the individual, balancing the improvement in microvascular complications with the risk of hypoglycemia. A reasonable goal of therapy might be an A1C value of &le;7.0 percent for most patients (using an assay in which the upper limit of normal is 6.0 percent). Glycemic targets are generally set somewhat higher for older patients and those with comorbidities or a limited life expectancy and little likelihood of benefit from intensive therapy. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Glycemic targets'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Multifactorial risk reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vigorous cardiac risk reduction (smoking cessation,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , blood pressure control, reduction in serum lipids, preferably using a statin, diet, exercise, and, in high-risk patients, an angiotensin converting enzyme inhibitor) should be a top priority for all patients with type 2 diabetes.",
"   </p>",
"   <p>",
"    In spite of evidence that aggressive risk factor reduction lowers the risk of both micro- and macrovascular complications in patients with diabetes, the vast majority of patients do not achieve recommended goals for A1C, blood pressure control, and management of dyslipidemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of medical care in adults with diabetes mellitus\", section on 'Multifactorial risk factor reduction'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/1\">",
"      The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/2\">",
"      Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353:2643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/3\">",
"      Klein R, Klein BE, Moss SE, Cruickshanks KJ. Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Arch Intern Med 1994; 154:2169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/4\">",
"      Bash LD, Selvin E, Steffes M, et al. Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy: Atherosclerosis Risk in Communities (ARIC) Study. Arch Intern Med 2008; 168:2440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/5\">",
"      Hemmingsen B, Lund SS, Gluud C, et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011; :CD008143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/6\">",
"      Coca SG, Ismail-Beigi F, Haq N, et al. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med 2012; 172:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/7\">",
"      Nathan DM. Understanding the long-term benefits and dangers of intensive therapy of diabetes. Arch Intern Med 2012; 172:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/8\">",
"      Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/9\">",
"      Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/10\">",
"      United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995; 310:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/11\">",
"      Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/12\">",
"      Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/13\">",
"      ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/14\">",
"      Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/15\">",
"      Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010; 376:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/16\">",
"      ACCORD Study Group, ACCORD Eye Study Group, Chew EY, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/17\">",
"      Khaw KT, Wareham N, Bingham S, et al. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004; 141:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/18\">",
"      Kuusisto J, Mykk&auml;nen L, Py&ouml;r&auml;l&auml; K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994; 43:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/19\">",
"      Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/20\">",
"      Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010; 362:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/21\">",
"      Selvin E, Coresh J, Golden SH, et al. Glycemic control, atherosclerosis, and risk factors for cardiovascular disease in individuals with diabetes: the atherosclerosis risk in communities study. Diabetes Care 2005; 28:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/22\">",
"      Meigs JB, Singer DE, Sullivan LM, et al. Metabolic control and prevalent cardiovascular disease in non-insulin-dependent diabetes mellitus (NIDDM): The NIDDM Patient Outcome Research Team. Am J Med 1997; 102:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/23\">",
"      Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/24\">",
"      Kelly TN, Bazzano LA, Fonseca VA, et al. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009; 151:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/25\">",
"      Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011; 343:d4169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/26\">",
"      Hemmingsen B, Lund SS, Gluud C, et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 2011; 343:d6898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/27\">",
"      Abraira C, Colwell J, Nuttall F, et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Arch Intern Med 1997; 157:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/28\">",
"      Abraira C, Duckworth WC, Moritz T, VADT Group. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes Obes Metab 2009; 11:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/29\">",
"      Gerstein HC, Riddle MC, Kendall DM, et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007; 99:34i.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/30\">",
"      ACCORD Study Group, Buse JB, Bigger JT, et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007; 99:21i.",
"     </a>",
"    </li>",
"    <li>",
"     The National Heart, Lung, and Blood Institute. Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Questions and Answers about the ACCORD Trial. file://www.nhlbi.nih.gov/health/prof/heart/other/accord/ (Accessed on February 14, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/32\">",
"      Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/33\">",
"      Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010; 340:b4909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/34\">",
"      ACCORD Study Group, Gerstein HC, Miller ME, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011; 364:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/35\">",
"      Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010; 363:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/36\">",
"      Kooy A, de Jager J, Lehert P, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 2009; 169:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/37\">",
"      Satoh N, Ogawa Y, Usui T, et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003; 26:2493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/38\">",
"      Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/39\">",
"      Pf&uuml;tzner A, Marx N, L&uuml;bben G, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005; 45:1925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/40\">",
"      Koshiyama H, Shimono D, Kuwamura N, et al. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001; 86:3452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/41\">",
"      Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/42\">",
"      Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 2004; 164:2147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/43\">",
"      Deedwania PC, Fonseca VA. Diabetes, prediabetes, and cardiovascular risk: shifting the paradigm. Am J Med 2005; 118:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/44\">",
"      Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 2001; 322:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/45\">",
"      Selvin E, Wattanakit K, Steffes MW, et al. HbA1c and peripheral arterial disease in diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care 2006; 29:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/46\">",
"      Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010; 375:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/47\">",
"      Shurraw S, Hemmelgarn B, Lin M, et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med 2011; 171:1920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/48\">",
"      Huang ES, Zhang Q, Gandra N, et al. The effect of comorbid illness and functional status on the expected benefits of intensive glucose control in older patients with type 2 diabetes: a decision analysis. Ann Intern Med 2008; 149:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/49\">",
"      Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/50\">",
"      Handelsman Y, Mechanick JI, Blonde L, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract 2011; 17 Suppl 2:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/51\">",
"      Gray A, Raikou M, McGuire A, et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group. BMJ 2000; 320:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/52\">",
"      Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care 1997; 20:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/53\">",
"      Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997; 20:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/25/7578/abstract/54\">",
"      Vijan S, Hofer TP, Hayward RA. Estimated benefits of glycemic control in microvascular complications in type 2 diabetes. Ann Intern Med 1997; 127:788.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1760 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-FC043B0C43-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_25_7578=[""].join("\n");
var outline_f7_25_7578=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HYPERGLYCEMIA AND MICROVASCULAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      United Kingdom Prospective Diabetes Study",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Post-trial monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Kumamoto study",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ADVANCE trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Veteran's Affairs Diabetes Trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11243121\">",
"      ACCORD trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Microvascular summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MACROVASCULAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Intensive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - UKPDS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - VACSDM/VADT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - ACCORD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21498942\">",
"      Post-termination monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - ADVANCE",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Macrovascular summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Metformin therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Thiazolidinediones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Prediabetes and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      GLYCEMIC TARGETS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      COST OF INTENSIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Microvascular complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Macrovascular complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Target A1C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Multifactorial risk reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1760\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1760|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/5/17502\" title=\"figure 1\">",
"      HbA1c with intensive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/55/16254\" title=\"figure 2\">",
"      Diabetes endpoints and control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/32/37389\" title=\"figure 3\">",
"      Microvascular endpoint and control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/2/31790\" title=\"figure 4A\">",
"      Metformin in type 2 DM I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/62/20462\" title=\"figure 4B\">",
"      Metformin in type 2 DM II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/32/43533\" title=\"figure 5\">",
"      CV risk before diabetes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3078?source=related_link\">",
"      Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=related_link\">",
"      Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=related_link\">",
"      Glycemic control and vascular complications in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28569?source=related_link\">",
"      Heart failure in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=related_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/1/40980?source=related_link\">",
"      Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=related_link\">",
"      Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/40/22144?source=related_link\">",
"      Patient information: The ABCs of diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=related_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=related_link\">",
"      Prediction and prevention of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=related_link\">",
"      Prevalence of and risk factors for coronary heart disease in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=related_link\">",
"      Thiazolidinediones in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/42/682?source=related_link\">",
"      Treatment of type 2 diabetes mellitus in the elderly patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_25_7579="CSF drug conc with inflammation";
var content_f7_25_7579=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62934&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62934&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Peak CSF concentrations of cephalosporins in bacterial meningitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Cephalothin",
"       </td>",
"       <td>",
"        0.16-0.31&nbsp;&micro;g/mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cefoxitin",
"       </td>",
"       <td>",
"        &lt;1.56-12.5&nbsp;&micro;g/mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cefuroxime",
"       </td>",
"       <td>",
"        4.3-9.3&nbsp;&micro;g/mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cefotaxime",
"       </td>",
"       <td>",
"        6.8-27.2&nbsp;&micro;g/mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ceftizoxime",
"       </td>",
"       <td>",
"        &lt;0.5-29.0&nbsp;&micro;g/mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ceftriaxone",
"       </td>",
"       <td>",
"        2-42&nbsp;&micro;g/mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ceftazidime",
"       </td>",
"       <td>",
"        2.5-30&nbsp;&micro;g/mL",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_25_7579=[""].join("\n");
var outline_f7_25_7579=null;
var title_f7_25_7580="Elicited signs of catatonia";
var content_f7_25_7580=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F66229&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F66229&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Elicited signs of catatonia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Feature",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description and examples",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ambitendency",
"       </td>",
"       <td>",
"        The patient appears \"stuck\" in an indecisive, hesitant movement when the examiner verbally contradicts his or her own nonverbal signal. As an example, the examiner offers his hand as if to shake hands while stating, \"Do not shake my hand.\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Waxy flexibility",
"       </td>",
"       <td>",
"        The rigid patient's initial resistance to the examiner's manipulations is gradually overcome, allowing re-positioning (as in bending a candle).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Automatic obedience",
"       </td>",
"       <td>",
"        The patient moves with the examiner's light pressure into a new position despite instructions to the contrary. The new position may then be maintained despite instructions to the contrary. Test bilaterally as this sign may result from contralateral brain lesions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Negativism",
"       </td>",
"       <td>",
"        The patient resists the examiner's manipulations with strength equal to that applied (rigidity); social negativism may include sleeping under the bed, turning away when addressed, refusing to open the eyes, and closing the mouth when offered food or liquids.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stimulus-bound behavior",
"       </td>",
"       <td>",
"        The patient's behavior is tied to certain stimuli. As an example, the examiner states, \"When I touch my nose, you touch your chest,\" and the patient touches his nose in a mirrored behavior despite understanding the instruction.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from:",
"     <br>",
"      <ol>",
"       <li>",
"        Fink M, Taylor MA. The catatonia syndrome: Forgotten but not gone. Arch Gen Psychiatry 2009; 66:1173.",
"       </li>",
"       <li>",
"        American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC, American Psychiatric Association, 2000.",
"       </li>",
"       <li>",
"        Bush G, Fink M, Petrides G, et al. Catatonia. I. Rating scale and standardized examination. Acta Psychiatr Scand 1996; 93:129.",
"       </li>",
"       <li>",
"        Greenhalgh J, Knight C, Hind D, et al. Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies. Health Technol Assess 2005; 9:1.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_25_7580=[""].join("\n");
var outline_f7_25_7580=null;
var title_f7_25_7581="Revised FLACC pain score";
var content_f7_25_7581=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F81819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F81819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Revised FLACC pain score",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Categories",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Scoring",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        0",
"       </td>",
"       <td class=\"subtitle2\">",
"        1",
"       </td>",
"       <td class=\"subtitle2\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <p>",
"         <strong>",
"          F",
"         </strong>",
"        </p>",
"        <p>",
"         Face",
"        </p>",
"       </td>",
"       <td>",
"        No particular expression or smile",
"       </td>",
"       <td>",
"        Occasional grimace or frown, withdrawn, disinterested;",
"        <em>",
"         appears sad or worried",
"        </em>",
"       </td>",
"       <td>",
"        Frequent to constant frown, clenched jaw, quivering chin;",
"        <em>",
"         distressed-looking face: expression of fright or panic",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <p>",
"         <strong>",
"          L",
"         </strong>",
"        </p>",
"        <p>",
"         Legs",
"        </p>",
"       </td>",
"       <td>",
"        Normal position or relaxed",
"       </td>",
"       <td>",
"        Uneasy, restless, tense;",
"        <em>",
"         occasional tremors",
"        </em>",
"       </td>",
"       <td>",
"        Kicking, or legs drawn up;",
"        <em>",
"         marked increase in spasticity, constant tremors or jerking",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <p>",
"         <strong>",
"          A",
"         </strong>",
"        </p>",
"        <p>",
"         Activity",
"        </p>",
"       </td>",
"       <td>",
"        Lying quietly, normal position, moves easily",
"       </td>",
"       <td>",
"        Squirming, shifting back and forth, tense;",
"        <em>",
"         mildly agitated (eg, head back and forth, aggression); shallow and splinting respirations, intermittent sighs",
"        </em>",
"       </td>",
"       <td>",
"        Arched, rigid, or jerking;",
"        <em>",
"         severe agitation, head banging; shivering (not rigors); breath-holding, gasping or sharp intake of breath; severe splinting",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <p>",
"         <strong>",
"          C",
"         </strong>",
"        </p>",
"        <p>",
"         Cry",
"        </p>",
"       </td>",
"       <td>",
"        No cry (awake or asleep)",
"       </td>",
"       <td>",
"        Moans or whimpers, occasional complaint;",
"        <em>",
"         occasional verbal outburst or grunt",
"        </em>",
"       </td>",
"       <td>",
"        Crying steadily, screams or sobs, frequent complaints;",
"        <em>",
"         repeated outbursts, constant grunting",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <p>",
"         <strong>",
"          C",
"         </strong>",
"        </p>",
"        <p>",
"         Consolability",
"        </p>",
"       </td>",
"       <td>",
"        Content, relaxed",
"       </td>",
"       <td>",
"        Reassured by occasional touching, hugging, or being talked to, distractable",
"       </td>",
"       <td>",
"        Difficult to console or comfort;",
"        <em>",
"         pushing away caregiver, resisting care or comfort measures",
"        </em>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This pain score can be used to assess pain from burns and other etiologies for preverbal children.",
"    <br>",
"     <ul>",
"      <li>",
"       Each of the five categories (F) Face; (L) Legs; (A) Activity; (C) Cry; (C) Consolability is scored from 0-2, which results in a total score between zero and ten.",
"      </li>",
"      <li>",
"       <strong>",
"        Patients who are awake:",
"       </strong>",
"       Observe for at least 1-2 minutes. Observe legs and body uncovered. Reposition patient or observe activity, assess body for tenseness and tone. Initiate consoling interventions if needed.",
"      </li>",
"      <li>",
"       <strong>",
"        Patients who are asleep:",
"       </strong>",
"       Observe for at least 2 minutes or longer. Observe body and legs uncovered. If possible reposition the patient. Touch the body and assess for tenseness and tone.",
"      </li>",
"      <li>",
"       The revised FLACC can be used for children with cognitive disability. The additional descriptors (in italics) are included with the original FLACC. The nurse can review the descriptors within each category with parents. Ask them if there are additional behaviors that are better indicators of pain in their child. Add these behaviors to the tool in the appropriate category.",
"      </li>",
"     </ul>",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission. Copyright &copy; 2002 The Regents of the University of Michigan.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_25_7581=[""].join("\n");
var outline_f7_25_7581=null;
var title_f7_25_7582="Thyroxine metabolism";
var content_f7_25_7582=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F57919&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F57919&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 580px\">",
"   <div class=\"ttl\">",
"    Thyroxine metabolism in nonthyroidal illness",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 560px; height: 270px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The inhibition of 5'- monodeiodinase in nonthyroidal illness leads to decreased conversion of T4 to T3 and reduced metabolism of reverse T3.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_25_7582=[""].join("\n");
var outline_f7_25_7582=null;
var title_f7_25_7583="Treatment of PH";
var content_f7_25_7583=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 597px\">",
"   <div class=\"ttl\">",
"    Treatment of pulmonary hypertension algorithm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 577px; height: 484px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NYHA: New York Heart Association; IV: intravenous; SC: subcutaneous.",
"    </div>",
"    <div class=\"reference\">",
"     Original figure modified for this publication. Reproduced from: Barst RJ, Gibbs US, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54:S78. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_25_7583=[""].join("\n");
var outline_f7_25_7583=null;
